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INTRODUCTION 
 Diabetes mellitus is a major cause of morbidity and mortality, 
the world over. It is the most prevalent endocrine disorder that exists in 
the world today. It is estimated that the total number of diabetics will 
increase worldwide from 171 million in 2000 to 366 million in 2030.5 
 It is a chronic metabolic disorder resulting from a relative or 
absolute deficiency of insulin leading to hyperglycaemia. Diabetes 
mellitus is classified into two broad categories, type 1 and type 2 
depending on the pathogenic process leading to hyperglycaemia. An 
autoimmune destruction of the beta cells of the islets of Langerhans of 
the pancreas, the cells responsible for insulin production, causes type 1 
diabetes mellitus (insulin-dependent diabetes mellitus [IDDM]). Type 
2 diabetes mellitus (non-insulin dependent diabetes mellitus [NIDDM]) 
is a heterogeneous disorder characterised by a varying proportion of 
insulin resistance, decreased insulin production and increased glucose 
production. While type 1 diabetes usually occurs below the age of 30 
years, 5-10% of cases are diagnosed after 30 years of age. Type 2 
diabetes occurs with increasing age, but it has been found to occur in 
children and obese adolescents. Of the diabetic population, 
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approximately 10% have type 1 diabetes, a majority comprising of type 
2 diabetes. 
 Diabetes is known to cause an array of microvascular and 
macrovascular complications such as nephropathy, neuropathy, 
coronary artery disease, peripheral vascular disease and 
cerebrovascular disease. Among the ophthalmic complications are 
corneal abnormalities, iris neovascularisation, glaucoma and cataracts. 
However the commonest ophthalmic complication remains diabetic 
retinopathy, a sight threatening disorder, which is its microvascular 
complication. It may have a devastating impact on an individual's 
quality of life, and hence early detection through routine screening for 
patients at risk for developing diabetic retinopathy and those who may 
progress to a severe stage is essential to reduce preventable blindness 
from this disease.  
 Diabetic retinopathy, in general, has been observed to progress 
through the stages of mild to moderate and severe non-proliferative 
diabetic retinopathy, in an orderly fashion, before the development of 
proliferative diabetic retinopathy and its vision-threatening 
complications such as vitreous haemorrhage and tractional retinal 
detachment. Several factors are known to influence the severity and 
3 
progression of diabetic retinopathy such as the duration of diabetes, 
glycaemia control, blood pressure, serum creatinine concentration and 
the body mass index. 
 Vitamin D, until recently was known for its effects on the 
musculoskeletal system, however various studies have now 
demonstrated the non-traditional benefits of Vitamin D, including its 
role  in  diabetes  mellitus.  Chiu  KC  et.  Al.  in  2004  showed  that  it  is  
required for normal insulin secretion and glucose homeostasis.6 It has 
been shown to have anti-inflammatory, antioxidant, antiangiogenic and 
antiproliferative functions. 
 Vitamin D deficiency is a growing health care concern. Several 
studies have demonstrated widespread vitamin D deficiency and 
insufficiency, both in patients with a wide spectrum of diseases and in 
apparently healthy individuals. Holick, M.F. in 2007 found that an 
estimated 1 billion people were affected by vitamin D deficiency.7 
 The role of vitamin D on insulin secretion and sensitivity has 
been  established  by  Norman  A.  W.  et.  Al.  in  1980,  Chertow  B.S.  et.  
Al. in 1983 and Cade C. et. Al. in 1986, leading to a proposal that it 
may influence the occurrence as well as treatment of diabetes.8,9,10 A 
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reduced risk of development of diabetes has been demonstrated in 
patients on vitamin D supplementation has been demonstrated by Pittas 
et al.11 These results suggested that improving vitamin D status in 
patients with type 2 diabetes may play a role in controlling the micro-
vascular complications of diabetes, namely diabetic retinopathy. 
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REVIEW OF LITERATURE 
 Diabetic retinopathy is a distressing microvascular complication 
of both type 1 and type 2 diabetes mellitus. Damage observed in 
diabetic retinopathy is through the formation of advanced 
glycosylation end products and increased metabolism through the 
sorbitol and hexosamine pathway leading to increased production of 
several growth factors such as vascular endothelial growth factor 
(VEGF), thereby aggravating the disease process. 
 The cause of loss of vision in diabetic retinopathy may be 
macular oedema, macular ischemia, vitreous haemorrhage and 
tractional retinal detachment. In patients with background diabetic 
retinopathy, the progression to vision threatening diabetic retinopathy 
at 1 year has been estimated to be 5% and for pre-proliferative 
retinopathy the same has been found to be 15%. 
 According to the WHO publication of 2004, there are about 31.7 
million patients suffering from diabetes in India, resulting in the 
highest ranking worldwide. This number is predicted to progress to 
79.4 million by 2030. 
6 
 The Chennai Urban Rural Epidemiology Study (CURES) I 
demonstrated the prevalence of diabetic retinopathy as 17.6%. The 
Chennai  Urban  Rural  Epidemiology  Study  (CURES)  2  study  was  
undertaken to demonstrate the association between diabetic retinopathy 
and serum lipids in South Indian urban population.12 
 Early Treatment Diabetic Retinopathy Study (ETDRS) was a 
multicentric, randomised clinical trial. It evaluated the role of argon 
laser photocoagulation and aspirin treatment in the management of 
non-proliferative or early proliferative diabetic retinopathy.13 The 
ETDRS group proposed the ETDRS classification which is the 
modified Airlie House classification of diabetic retinopathy and was 
used  in  the  DRS.72 It classified diabetic retinopathy into mild, 
moderate, severe, very severe, early PDR and high risk PDR based 
upon the characteristic lesions observed. Seven standard photographic 
fields were used, with retention of the original standard, colour, non-
simultaneous stereoscopic photographs. This classification was more 
standardised and elaborative and reduced examiner bias.  
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HISTORY 
 Retinal manifestation of diabetes were first observed by Eduard 
Jaeger in 1856. This was possible only after the development of the 
direct ophthalmoscope in 1855. Albrecht Von Graefe apposed Jaeger’s 
findings, stating that there was no causal relationship between diabetes 
and retinopathy.  
 In 1872, Edward Nettleship provided the first histopathological 
evidence of “Cystoid Degeneration of the Macula” in patients with 
Diabetes in his publication. The proliferative changes occurring in 
Diabetic Retinopathy and the importance of tractional retinal 
detachments and vitreous haemorrhages were then described by 
Wilhelm Manz in 1876. 
 However during the early 20th century, the controversy remained 
regarding whether macular changes caused by diabetes or hypertension 
and arteriosclerosis. Arthur James Ballantyne in Glasgow, in the late 
20th century, provided further evidence to support the fact that diabetes 
was the cause for the retinopathy observed in these patients. 
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ANATOMY 
 The retina forms the inner coat of the eye ball, where the optical 
image  is  formed by  the  optical  system of  the  eye.  It  is  has  a  purplish  
red appearance due to the presence of visual purple in the rods. Its 
thickness ranges from 0.56mm in the peripapillary retina to 0.18 to 0.2 
at  the equator and about 0.1mm at  the ora serrata.  It  is  thinnest  at  the 
fovea. It has a surface area of 266 mm2. 
 It has an outer pigmented and inner neurosensory layer, both of 
which are derived embryologically from the neuroectoderm. The outer 
retinal pigment epithelium develops form the outer layer of the optic 
cup and the inner neurosensory layer develops from the inner layer of 
the optic cup. The neural retina terminates anteriorly at the ora serrata.  
Specialised Areas of the Neural Retina: 
Macula Lutea 
 It is an oval, yellowish area at the posterior pole of the retina, 
lying temporal to the optic disc. It measures about 5.5 mm in diameter. 
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Fovea Centralis 
 It is a depressed area in the centre of the macula lutea, 
measuring about 1.85mm in diameter. The floor is called the foveola 
and the sides of the depression are called Clivus. This depressed area is 
formed due to the nerve cells being displaced peripherally, leaving 
only the cones in the centre. There are no rods or blood vessels 
overlying the fovea. The fovea has the highest concentration of cones 
and hence represents the area of maximum visual acuity of the eye. It 
accounts for 5 degrees of the visual fields.  
 The foveola is located 2 disc diameters from the temporal edge 
of the optic disc and 1 mm below the horizontal meridian. It measures 
0.35 mm in diameter. The umbo is a depression at the centre of the 
foveola and is responsible for the foveolar reflex. The foveal avascular 
zone is situated outside the foveola, but inside the fovea. 
Optic Disc 
 It  is  about  1.5 mm in diameter.  All  the retinal  layers except  the 
nerve fibre layer end here. It is insensitive to light due to the absence of 
photoreceptors and is hence called the blind spot. It has a central 
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depression which is the physiological cup from where the central 
retinal vessels enter and leave the eye.  
Histology 
 The retina is composed of 10 layers, based on light microscopic 
findings. These, from outside to inside are: 
1.  The retinal pigment epithelium 
2.  The rods and cones 
3.  The external limiting membrane 
4.  The outer nuclear layer 
5.  The outer plexiform layer 
6.  The inner nuclear layer 
7.  The inner plexiform layer 
8.  The ganglion cell layer 
9.  The Nerve fibre layer 
10. The internal limiting membrane 
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Blood Supply 
It is from 2 sources: 
1. The Outer Lamina consisting of four layers namely the pigment 
epithelium, the layer of rods and cones, the external limiting 
membrane and the outer nuclear layer are supplied by the 
choriocapillaries. 
2. The Inner Lamina comprising of the remaining 6 layers namely 
the outer plexiform layer, inner nuclear layer, ganglion cell 
layer, nerve fibre layer and the internal limiting membrane is 
supplied by the central retinal artery and veins. 
3. The outer plexiform layer is supplied partially by the 
choriocapillaries and partially by the central retinal artery. 
Blood Retinal Barrier 
 The normal retinal capillaries are lined by endothelial cells 
which are bound together by intercellular junctions of the zonula 
occludens type. The free flow of solutes and fluids from the retinal 
vasculatures into the interstitium is prevented by these junctions hence 
12 
constituting the blood retinal barrier. These endothelial cells are 
surrounded by a basement membrane and pericytes. In diabetes, this 
blood retinal barrier has been found to be compromised leading to the 
characteristic changes observed in diabetic retinopathy.   
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EPIDEMIOLOGY 
 There are 171 million people worldwide suffering from diabetes 
mellitus, a figure which is predicted to be doubled by 2030, according 
to the 2004 WHO publication. In 2002, 5 million people were blind 
due to diabetic retinopathy, constituting 5% of the world blindness. 
The prevalence of diabetic retinopathy in India is found to vary 
between 10.5% to 26.2%. It is a leading cause of new blindness for 
individuals between 20 to 74 years of age in both developed and 
developing countries. This increasing incidence has lead to its 
inclusion in the "priority list" of "Vision 2020". 
 Type  1  diabetes  mellitus  (IDDM)  comprises  of  10-15%  of  all  
diabetics, the remaining 85% being type 2 diabetes mellitus (NIDDM). 
In type 1 diabetes of less than 5 years duration, diabetic retinopathy is 
seen in 13% of patients, which increases to 90% with a duration of 10-
15 years and 100% with a duration of greater than 20 years. 
 In NIDDM there is an increased occurrence of diabetic 
retinopathy with increasing duration of diabetes. For patients with 
duration of greater than 5 years, it has been found to have an estimated 
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prevalence of 40% in those taking insulin and 24% in those not taking 
insulin.  
 While patients with Type 1 diabetes have a high incidence of 
diabetic retinopathy, type 2 diabetes still accounts for the causation of 
a majority of the cases observed, due to its increased prevalence.  
 The prevalence of non-proliferative retinopathy, proliferative 
retinopathy and macular oedema was reported as 71%, 23% and 11% 
in  IDDM  and  47%,  6%  and  8%  in  NIDDM  respectively,  in  the  
WESDR. They reported a 10 year incidence of retinopathy in IDDM 
below  30  years  age  as  89%  and  that  above  30  years  age  as  79%.  In  
NIDDM patients greater the 30 years age the incidence of retinopathy 
is less in the estimates provided by more recent population-based 
studies.14,15 
 A more recent study which compiled data from a total of other 
eight  studies  including  WESDR,  was  an  effort  to  provide  a  more  
accurate estimate of the prevalence of retinopathy in patients who were 
40 years or older.16 The estimates of retinopathy were found to be 
lower than in the WESDR study.  All  of  these studies were performed 
at least 10 years after the WESDR study. This study stated that among 
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the diabetics the crude prevalence of retinopathy was 40%, while 8% 
of diabetic patients suffered from visual loss due to retinopathy. 
 Due to advances in the management of diabetes, the prevalence 
of diabetic retinopathy and its consequential visual loss has not been 
found to increase, accompanying the increased prevalence of diabetes 
which has been noted in the recent years. This is attributed to a more 
stringent glycaemia control in patients with IDDM. This is reflected by 
the fact that up to 85% patients were found to be using more than 3 
injections of insulin daily and up to 91% of patients were practising 
self monitoring of blood glucose. This resulted in a decrease in the 
mean levels of HbA1c to 7.6% and up to 33% diabetics attaining the 
ADA guidelines of a glycosylated haemoglobin level of less than 7%, 
as observed in the WESDR. 
 Following the UKPDS study there was an increase in the 
management of NIDDM using multiple oral hypoglycaemic agents, as 
opposed to the use of only one such drug prior to this study. This 
resulted  in  a  reduction  of  the  mean  HbA1c levels  from 7.8% to  7.2% 
and a 41% increase in patients achieving mean HbA1c levels of less 
than 7%.17  
16 
 Factors that may increase the incidence of diabetic retinopathy 
include hypertension, obesity, hyperlipidemia, pregnancy and oral 
contraceptives, glomerulosclerosis and a sudden shift from oral 
hypoglycaemic agents to insulin. 
FACTORS INFLUENCING DIABETIC RETINOPATHY 
1. Duration of diabetes 
 This  is  one  of  the  most  consistent  risk  factors  for  the  
development and increase in severity of diabetic retinopathy. It is a 
significant risk factor for the development of maculopathy. In IDDM, 
retinopathy develops at least 3-4 years after disease onset. PDR was 
found in 33% and 50% of women and men respectively following 20 
year duration of diabetes. Since the duration of development of type 2 
diabetes is difficult to determine, retinopathy may present as an initial 
sign soon after diagnosis. 20 years after the development of diabetes, 
100% of patients with IDDM and 60% of patients with NIDDM were 
found to have developed proliferative diabetic retinopathy. In both type 
1 and type 2 diabetes duration of diabetes as a factor for prevalence of 
macular oedema was identical.15 
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2. Age 
 An increase in the prevalence of retinopathy has been observed 
as age advances. The hormonal changes during puberty influence the 
progression of retinopathy. Elevated Insulin like Growth Factor I (IGF 
I) is produced under the influence of growth hormone and closely 
resembles a chain of insulin. It is known to enhance the development 
of diabetic retinopathy. 
3. Sex incidence  
 An increased incidence of proliferative diabetic retinopathy was 
observed in men with an earlier onset of diabetes than women, in the 
WESDR study.  However  besides  this,  no  significant  difference  in  the  
prevalence or progression of retinopathy was observed between males 
and females in the WESDR study. 
4. Race 
 Blacks have a 20% higher incidence then whites. Several studies 
have demonstrated that the prevalence of retinopathy in NIDDM was 
greater in African Americans.18,19,20,21  In  the  NHANES (1988-94  and  
2005-8) and the MESA, retinopathy was more frequent in Mexican 
18 
Americans then the non-Hispanic whites who were 40 years of age or 
older.  
5. Genetic factors  
 Data from several studies has revealed familial clustering of 
diabetic retinopathy suggesting a genetic susceptibility. Patients with 
HLA DR 4 and DR 5 phenotype have been found to have an increased 
risk of proliferative diabetic retinopathy. HLA B 15 individuals are 
more likely to develop diabetic retinopathy, while individuals with 
HLA B 7 are 4 times less likely to develop PDR. 
6. Glycaemic control 
 Retrospective studies measuring glycosylated haemoglobin, 
evaluating long term control of blood glucose have suggested that 
hyperglycaemia is closely associated with the development of 
retinopathy.  
 According to the Diabetic Control and Complications Trial 
(DCCT),  a  10%  decrease  in  HbA1c  (from  8%  to  7.2%)  results  in  a  
decrease in incidence of diabetic retinopathy by 35% to 40%. The 
results of the DCCT are as follows: 
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· Intensive therapy reduced the first appearance of any retinopathy 
by 27% and clinically meaningful diabetic retinopathy by 35 to 
74%. 
· Intensive therapy also reduced the development of other 
microvascular complications such as reduction of 
microalbuminuria by 35%, clinical proteinuria by 56% and 
clinical neuropathy by 60%. 
· Intensive treatment included insulin administration at least thrice 
daily with dose adjustment on the basis of self blood glucose 
monitoring with aim of achieving normoglycaemia. 
 However this study was based on the results obtained from 
patients suffering from IDDM and not NIDDM.22 
 On the other hand UKPDS, conducted between 1977 to 1991, 
included only NIDDM patients. It evaluated glycaemia control with 
either insulin or sulphonylurea. The study concluded that intensive 
blood glucose control reduced the progression of retinopathy and the 
development of other microvascular complications of diabetes. 
20 
 These studies conclusively demonstrate that stringent control of 
blood glucose, both in patients with IDDM and NIDDM, is of utmost 
importance to decrease the sight threatening complications resulting 
from retinopathy. The studies further emphasized the importance 
attaining the ADA guidelines of a target of HbA1c levels below 7% 
and suggest that the earlier this level is achieved after the diagnosis of 
diabetes, the lower the risk for development and progression of 
retinopathy. 
7. Hypertension 
 Increased blood pressure levels enhance the risk of development 
and progression of retinopathy. A similar association has been found 
between an increase in diastolic blood pressure and a rise in the 
incidence of diabetic macular oedema. The UKPDS demonstrated on 
reducing the systolic blood pressure, decrease in the incidence of 
microvascular complications of diabetes including retinopathy was 
observed. 
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8. Pregnancy 
 Pregnancy creates a state of insulin resistance thereby promoting 
the progression of retinopathy. 
9. Protienuria and diabetic nephropathy 
 Diabetic nephropathy has been found to be a significant risk 
factor in the development and progression of diabetic retinopathy. 
10. Serum lipids 
 In the ETDRS, higher levels of serum lipids at baseline were 
associated with an increased incidence of hard exudates at the macula 
and decreased visual acuity. Patients with hypercholesterolemia and 
receiving insulin therapy, demonstrated an increase in the number of 
hard exudates on fundus evaluation. 14,15 
11. Smoking 
 It has been suggested that smoking could aggravate retinal 
hypoxia by promoting aggregation of platelets and causing 
vasoconstriction of retinal vessels as a result of increased carbon 
22 
monoxide concentrations. However most studies, showed no 
association between smoking and retinopathy.14,15 
12. Alcohol 
 In patients with IDDM, alcohol intake was found to decrease the 
incidence of PDR in some studies.14,15 In the UKPDS, an increased 
alcohol consumption was found to be related to an increased incidence 
of retinopathy only in newly diagnosed young men with NIDDM. 
13. Ocular factors   
 Glaucoma, myopia and retino-choroidal scarring from trauma 
and inflammation have been proposed to protective against the 
development of retinopathy. 
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CLASSIFICATION 
 The most wide used classification internationally is that 
proposed by the Early Treatment Diabetic Retinopathy Study (ETDRS) 
or the modified Airlie House Classification. It gives a better 
understanding regarding the progression and management of the 
disease. 
ETDRS Classification of diabetic retinopathy 
I. NPDR (Non Proliferative Diabetic Retinopathy) 
 It is characterised by configurational changes in the veins, 
exudates and retinal haemorrhages. The severity of retinopathy is sub-
classified as 
a. Mild NPDR: 
At least one microaneurysms and definition not met for 
moderate NPDR. 
These patients have a 5 % risk of progressing to PDR within 
1 year and a 15 % risk of progressing to high-risk PDR 
within 5 years. 
 
24 
b. Moderate NPDR: 
· Severe retinal haemorrhages (more than ETDRS 
standard photograph 2A: about 20 medium-large per 
quadrant) in 1-3 quadrants or mild intraretinal 
microvascular abnormalities (IRMA). 
· Significant venous beading can be present in no more 
than 1 quadrant. 
· Cotton wool spots are commonly present. 
The risk of progression to PDR  is 12-27 % within 1 year 
and 33 % within 5 years. 
c. Severe NPDR: 
The 4-2-1 rule; one or more of: 
· Severe haemorrhages in all 4 quadrants 
· Significant venous beading in 2 or more quadrants 
· Moderate IRMA in 1 or more quadrants 
The risk of developing PDR is 52 % within 1 year and 60 
% within 5 years. 
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d. Very severe NPDR 
Two or more of the criteria for severe NPDR.  
The risk of developing PDR is 75 % within 1 year. 
II. Proliferative diabetic retinopathy (PDR) 
a. Early 
New vessels on the disc (NVD) or new vessels elsewhere 
(NVE), but extent insufficient to meet the high-risk criteria. 
The risk of developing high-risk PDR within 5 years is 75 %. 
b. High-risk  
· New vessels on the disc (NVD) greater than ETDRS 
standard photograph 10A (about ½ disc area) 
· Any NVD with vitreous or preretinal haemorrhage 
· NVE  greater  than  ½  disc  area  with  vitreous  or  
preretinal haemorrhage (or haemorrhage with 
presumed obscured NVD/E) 
Macular oedema can be classified as: 
· Focal 
· Diffuse 
26 
· Ischemic  
· Mixed 
Clinically significant macular oedema (CSME) was defined in ETDRS 
as: 
· Retinal thickening within 500 microns of the centre of the 
macula 
· Exudates within 500 microns of the centre of the macula, if 
associated with retinal thickening (which may be outside the 500 
microns) 
· Retinal thickening one disc area (1500 microns) or larger, any 
part  of  which  is  within  one  disc  diameter  of  the  centre  of  the  
macula.  
  
  
 
 
FIG.1 - MILD NON PROLIFERATIVE DIABETIC 
RETINOPATHY 
  
  
 
FIG.2 - MODERATE NON PROLIFERATIVE DIABETIC 
RETINOPATHY 
 
 
  
  
 
 
FIG.3 - SEVERE NON PROLIFERATIVE DIABETIC 
RETINOPATHY 
 
 
  
  
 
FIG.4 - VERY SEVERE NON PROLIFERATIVE DIABETIC 
RETINOPATHY 
 
 
  
  
FIG.5 - FLORID NEW VESSELS ON THE DISC (NVD) IN 
HIGH RISK PROLIFERATIVE DIABETIC RETINOPATHY 
 
 
  
  
 
FIG.6 - PRE-RETINAL HAEMORRHAGE WITH NEW 
VESSELS ELSEWHERE (NVE) 
 
 
  
  
 
FIG.7 - MACULAR SUB HYALOID HAEMORRHAGE 
 
 
 
 
  
  
 
FIG.8 - VITREOUS HAEMORRHAGE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
FIG.9 - TRACTIONAL RETINAL DETACHMENT 
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PATHOGENESIS OF DIABETIC RETINOPATHY 
 Structural, rheological and biochemical factors contribute to the 
development of diabetic retinopathy. 
I) Structural changes 
1. Capillary basement membrane thickening 
 Electron microscopy has proved marked thickening of the 
basement membrane, with swiss-cheese like vacuolization and 
deposition of fibrillar collagen which stains positive for type III 
collagen. 
2. Loss of microvascular intramural pericytes 
 In digest preparation they have been noted as empty, balloon 
like spaces bulging from the side of the capillary wall. This is probably 
related to the action of the sorbitol pathway. 
3. Loss of endothelial cells and endothelial cell dysfunction 
 FFA has demonstrated that acellular capillaries are non-
functional and appear as dark spaces on the angiogram. The endothelial 
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cell junctions become loose which could be related to the reduced 
expression of ZO-1 protein. Fenestrations appear in the endothelial cell 
cytoplasm.  
II) Rheological changes 
1. Platelet abnormalities 
 An increased platelet adhesiveness and aggregation and 
decreased platelet survival has been demonstrated by various studies. 
The cause of increased platelet aggregation may be due to elevated 
levels of Von Willebrand factor-Factor VIII, increased production of 
thrombaxane A2 by platelets and reduced prostaglandin production by 
endothelial cells 
2. Red blood cell abnormalities 
 A decreased deformability and increased formation of rouleaux 
aggregates has been shown. A multitude of factors contribute to local 
ischemia probably due to increased red cell aggregation such as 
increased level of fibrinogen  and alpha 2 globulin, inhibition of 
plasmin by alpha 2 globulin and diminished fibrinolytic response. The 
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increased erythrocyte aggregation results in increased blood viscosity 
and microinfarction of the retinal vasculature.  
III) Biochemical changes 
1. Prolonged hyperglycaemia 
 This is a major etiological agent for all microvascular 
abnormalities of diabetes including retinopathy. The cellular 
mechanisms postulated are as follows: 
· Prolonged hyperglycaemia alters the expression of genes leading 
to the formation of gene products that can alter cellular functions 
· Advanced glycation end products are formed by the non-
enzymatic binding of several sugars to proteins, which are long 
lived and play a causal role in diabetic complications 
· Chronic hyperglycaemia may produce accelerated oxidative 
stress in cells leading to increased formation of toxic end 
products. 
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2. Sorbitol pathway 
 It is the most prominent enzymatic mechanism suggested to 
cause diabetic retinopathy and other complications. Sorbitol formed 
from glucose by aldose reductase, is slowly converted by sorbitol 
reductase to fructose. Since the latter reaction is a slow process, 
sorbitol accumulates in toxic concentrations leading to endothelial cell 
damage and cellular oedema. 
3. Diacyl glycerol (DAG) and Protein Kinase C (PKC) 
 The level of DAG and the activity of PKC is elevated in patients 
with diabetes leading to decreased retinal blood flow.    
4. Insulin receptors and glucose transportation 
 In quantitative immunohistochemistry studies, GLUT 1 (glucose 
transporter 1) immunoreactivity was present in the retina of half the 
patients suffering from diabetes, however the implications of this 
finding remain unclear. 
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5. Vascular endothelial growth factor (VEGF) 
 It is an angiogenic factor. An upregulation of genes for its 
expression has been noted in hypoxia of proliferative diabetic 
retinopathy. It may also be responsible for macular oedema in diabetic 
retinopathy.  
 Hence the following sequence of events can be postulated in 
diabetic retinopathy: 
1. Hyperglycaemia with insufficient insulin is the starting point. 
Advanced glycation end products are formed due to 
nonenzymatic binding of several sugars to proteins. Chronic 
hyperglycaemic results in oxidative stress. 
2. Altered signalling of pathways involving protein kinase C, 
nuclear factor kappa-B and MAP kinase occurs due to increased 
polyol metabolism of glucose. 
3. This results in damage to RPE cells, endothelial cells, pericytes 
and neurons. Recruitment of inflammatory cells also occurs. 
4. Elevated growth hormone and reduced insulin levels alter the 
hepatic cell protein synthesis leading to dysproteinaemia. 
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5. Elevated fibrinogen and alpha 2 globulin result in increased red 
cell aggregation 
6. Elevated growth hormone is associated with increased 
production of Von Willebrand factor and reduced prostacyclin 
levels leading to increased platelet aggregation. 
7. Hyperglycaemia impairs prostacyclin production by endothelial 
cells. 
8. Impaired RBC and platelet aggregation impairs 
haemorheodynamics in the microcirculation. 
9. Impaired blood flow in the microcirculation caused by a 
sluggish flow rate or microinfarction leads to hypoxia and 
ischemia. 
10. Release of vasoactive compounds, coagulation factors, growth 
factors and adhesion molecules occurs leading to angiogenesis 
and tissue remodelling, breakdown and leakage of retinal vessels 
and transudation and exudation of blood elements into the retinal 
structure. 
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CLINICAL FEATURES 
 Diabetic retinopathy can be broadly classified into the 
proliferative and non-proliferative varieties. The hallmark of 
proliferative retinopathy being presence of new vessels in the retina 
and optic disc. The clinical features are as follows: 
1.  Microaneurysms 
 These are usually the first visible signs of diabetic reinopathy 
and the hallmark of NPDR. They are identified ophthalmoscopically as 
red dots, most commonly in the posterior pole. Their size ranges from 
15 to 60 microns in diameter. Histologically, they are hypercellular 
outpouchings of  the capillary wall.  On FFA, they can be identified as 
hyperfluorescence dots much more extensive than those identified 
clinically. Punctuate haemorrhages, in contrast show blocked 
fluorescence on FFA. Hence FFA can be used to distinguish between 
the two. 
2.  Hard exudates- 
 Hard exudates are small white or yellowish-white deposits with 
sharp margins. They are formed due to lipid extravasation and are 
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usually seen as discrete intra retinal deposits surrounding  
microaneurysms in a circinate ring. They are usually located in the 
outer layers of retina, but can be more superficial and may be seen as 
individual dots or confluent patches. In late stages subretinal exudates 
can be replaced by fibrotic plaques. 
3.  Soft exudates- 
 These are small, whitish, fluffy, superficial lesions that represent 
infarction of the retinal nerve fibre layer with accumulation of neuronal 
debris.  The  swollen  ends  of  the  disrupted  nerve  axons  are  known  as  
cystoids bodies.  
4.  Intraretinal Microvascular Abnormalities(IRMA)- 
 These are arteriovenous shunts that run from retinal arterioles to 
venules, bypassing the capillary bed. Hence they are seen in areas 
adjacent to marked capillary non-perfusion as fine, red, irregular 
intraretinal lines. 
5.  Venous abnormalities- 
 Venous changes observed include dilatation and tortuosity, 
sausage like segmentation, looping and beading consisting of focal 
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narrowing and dilatation. Abnormalities within one half disc diameter 
of the disc margin are ignored. These changes correlate with risk of 
developing proliferative changes. 
6.  Arteriolar abnormalities- 
 These are early markers of ischemic changes and include 
peripheral narrowing, silver-wiring and vascular obliteration. 
Abnormalities within one half disc diameter of the disc margin are 
ignored. 
7.  Capillary closure 
 It is one of the most important features of diabetic retinopathy, 
the extent and location of which is most accurately visualised on 
fluorescein angiography. 
8.  Retinal haemorrhages  
 They may be superficial or deep and are seen predominantly on 
the posterior pole. They may disappear only to reappear in a different 
area of the retina. Dot and blot haemorrhages are located within the 
compact deeper layers of the retina and result from venous 
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engorgement of capillaries. Deeper dark round haemorrhages 
representing hemorrhagic retinal infarcts may also occur. These may 
indicate subsequent progression to neovascularisation. Flame shaped 
haemorrhages arise in the nerve fibre layer from pre-capillary 
arterioles. 
9.   Preretinal haemorrhage- 
 Both boat shaped haemorrhages with a fluid level and round, 
oval or linear patches of the haemorrhage just anterior to the retina or 
under its internal limiting membrane are included in pre-retinal 
haemorrhages. Haemorrhages on the surface of the detached retina, is 
also considered to be preretinal haemorrhage.  
10. Diabetic macular oedema  
 Localised oedema is caused by focal leakage from dilated 
capillary segments or microaneurysms, while diffuse retinal oedema is 
caused by extensive capillary leakage. Lipid may also escape into the 
extravascular space and collect within the retina forming hard 
exudates. The fluid initially accumulates between the inner nuclear 
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layer and the outer plexiform layer, however it may eventually involve 
the entire thickness of the retina. 
11. New vessels- 
 These are most commonly seen at the posterior pole, though 
they may occur anywhere in the posterior pole. At least one quarter of 
the retina must be non-perfused prior to the development of 
proliferative changes. They appear as irregular vessels, often forming 
networks which may be accompanied by fibrous tissue which gradually 
increases as these vessels increase in size. Neovascularisation at the 
disc (NVD) is neovascularisation on or within one disc diameter of the 
optic disc, while neovascularisation elsewhere (NVE) is present away 
from the optic disc. Neovascularisation of the iris (NVI) may also 
develop which has a high risk for the development of neovascular 
glaucoma. 
12.  Vitreous changes  
 Posterior vitreous detachment may occur. New vessels on the 
retina are adherent to the posterior vitreous surface. As the vitreous 
starts separating, these vessels are stretched and may result in bleeding 
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into the vitreous cavity. Pre-retinal haemorrhages may also break into 
the vitreous. Vitreous condensation and fibrosis may also occur. 
13.  Retinal detachment 
 Tractional retinal detachment may occur, the extent and location 
of which depends on vitreo-retinal attachments. 
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CLINICAL EVALUATION 
1.  Visual Acuity 
 Visual loss mainly depends on the involvement of the macula. 
2. Indirect Ophthalmoscopy and slit lamp biomicroscopy with 90 D 
lens 
 This technique allows the examiner to integrate the view of the 
entire retina.  
3.  Direct Ophthalmoscopy 
 Though the area of retina examined is smaller, the increased 
magnification of this method allows detailed examination of the 
various retinal lesions. 
4.  Fundus Photography 
 The ETDRS classification used 7 standard photographic fields 
including one each centered on the disc, centered on the macula, 
temporal to the macula so that its nasal edge passes through the centre 
of the macula and the remaining four tangent to the vertical line 
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passing through the centre of the disc and horizontal lines passing 
through its upper and lower borders. It is useful for documentation of 
lesions and during follow up. 
5.   Fundus Fluorescein Angiography 
 This is one of the essential investigations needed in diabetic 
retinopathy. It can demonstrate microaneurysms, intraretinal 
microvascular abnormalities, new vessels and the extent of capillary 
closure. It provides the earliest evidence of a breech in the blood retinal 
barrier. Macular oedema can also be detected on FFA and classified 
into the focal, diffuse or ischemic variety. In eyes with asteroid 
hyalosis or hazy media, FFA may reveal lesions previously undetected 
on fundus examination. 
6.  Optical Coherence Tomography 
 It enables detection and quantification of macular oedema and 
vitreo-macular traction. The central macular thickness is used routinely 
to guide the decisions regarding the treatment modalities. The visual 
acuity may not correlate with OCT findings. 
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7.  Ultrasonography 
 It is an essential tool in the presence of opaque media to 
determine the status of the retina. It can detect the presence of retinal 
detachments, preretinal membranes and vitreous haemorrhage.  
  
42 
MANAGEMENT 
I. Non-Proliferative Diabetic Retinopathy 
 The Diabetic Retinopathy Study (DRS) and the Early Treatment 
Diabetic Retinopathy Study (ETDRS) are two landmark trials where 
laser photocoagulation was the principal modality of treatment. The 
results of these trials form the basis for the guidelines presently used in 
the treatment of diabetic retinopathy. The treatment for NPDR varies 
based upon the severity of the diabetic retinopathy and whether there is 
an associated clinically significant macular oedema.  
II.  Proliferative diabetic retinopathy 
 The  treatment  of  PDR  aims  at  achieving  two  main  goals,  one  
being the prevention of neovascular proliferation the other is to release 
the tractional forces exerted on the retina by the fibrovascular 
proliferations and posterior vitreous surface contraction. Good 
glycaemia control and its remarkable efficacy in discouraging the 
proliferation of new vessels have been proved (DCCT, 1993). 
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Laser photocoagulation 
 It involves transpupillary delivery of laser energy for the 
production of burns in the retina. It causes destruction of some retinal 
areas, allowing the blood and oxygen to be better delivered to the rest 
of the retina, thus having a beneficial role in retinal ischemia and 
decreasing the release of angiogenic factors. 
Scatter Photocoagulation for NPDR 
 It has been observed that the risk-benefit ratio of 
photocoagulation becomes more favourable as the retinopathy 
progresses from severe or very severe non proliferative stage or early 
proliferative stage. The risk of visual loss is significantly reduced by 
early scatter photocoagulation in patients with NIDDM (Ferris et al). 
Photocoagulation for Diabetic Macular Oedema 
 It is the treatment of choice in clinically significant macular 
oedema, which may be focal or grid laser photocoagulation. The focal 
laser photocoagulation used in ETDRS is indicated in cases of focal 
oedema, where the leaking microaneurysm can be identified. It 
involves direct application of laser burns to all leaking microaneurysms 
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in the edematous retina. Laser burns must be of 50 – 100 microns in 
diameter, 0.1 seconds exposure time and must be applied between 500 
– 3000 microns from the centre of the fovea. In ETDRS, the grid laser 
photocoagulation was used in cases of diffuse macular edema where 
focal areas of leakage could not be identified. It consists of light 
intensity burns with a spot size of 50-200 microns, exposure time of 
0.1 seconds and spaced more than 1 burn width apart. 
 The adverse effects of photocoagulation observed in some 
patients include the development of choroidal neovascularisation, 
which may lead to subretinal fibrosis. The risk factor for these adverse 
effects was the presence of extensive hard exudates depositions in the 
posterior pole in patients with hyperlipidemia. 
 The ETDRS study demonstrated that treated eyes had a 12 
percent loss of 15 letters of vision in 3 years compared to 24 percent in 
the untreated eyes. 
Photocoagulation for PDR 
 Mayer- Schwickerath developed the xenon arc photocoagulator, 
which was first used in PDR for the treatment of retinal new vessels. 
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 There has been wide agreement that prompt treatment must be 
initiated in most eyes with PDR that have well established NVD or 
vitreous or preretinal haemorrhages. Extensive neovascularisation in 
the anterior segment is a strong indication for scatter photocoagulation. 
Cryo applications or vitrectomy with endo photocoagulation are other 
alternatives which may be used if media opacities prevent visualisation 
of the retina. Signs of severe retinal ischemia increase the urgency to 
initiate scatter photo coagulation, as these eyes are more prone to 
anterior neovascularisation. 
ETDRS Protocol for Photocoagulation 
 The scatter protocol used argon blue green or green laser burns, 
with a spot size of 500 microns, exposure time of 0.1 seconds and of 
moderate intensity. The laser burns were applied one half burn width 
apart,  from  the  posterior  pole  to  the  equator.  A  total  of  1200  –  1600  
burns must be applied, which may be divided into two or more 
treatment sessions. Direct treatment was specified for patches of 
surface NVE that were two disc areas or less in extent. Confluent 
moderately intense burns were used in such cases that extended 500 
microns, beyond the edges of the patch. 
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 The ETDRS recommended that scatter treatment should be 
considered only in eyes nearing the high risk stage, where the risk-
benefit ratio of photocoagulation was approached a favourable range. It 
must be avoided in mild and moderate NPDR. 
 In patients  with very severe NPDR or moderate PDR, systemic 
factors must be taken into account while deciding when to begin 
treatment. Diabetic retinopathy may progress rapidly in pregnancy and 
renal failure, warranting earlier treatment. Macular oedema sometimes 
increases at least temporarily, after scatter photocoagulation. This may 
be followed by transient or persistent reduction of visual acuity. 
The six factors to be considered at follow up are - 
1. Change in new vessels since the last visit or last photocoagulation. 
2. Appearance of new vessels  
3. Frequency and extent of vitreous haemorrhages since last visit 
4. Status of vitreous detachment 
5. Extent of photocoagulation scars 
6. Extent of tractional retinal detachment and fibrous proliferation 
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 When additional scatter treatment is carried out using the above 
mentioned protocol, burns are placed between the treatment scars, 
sparring the area within 500 microns of the centre of macula using 
burns not larger than 200 microns. The areas chosen are generally 
those in which new vessels. 
Anti-VEGF drugs 
 Currently 3 anti-VEGFs are available, Ranibizumab (Lucentis), 
Pegaptinib (Macugen) and Bevacizumab (Avastin). Vascular 
endothelial growth factor (VEGF) has been found responsible for most 
of the proliferative changes in diabetic retinopathy. Hence intravitreal 
injections of anti-VEGF agents have been postulated to have 
significant role in treatment. 
 Several studies have established its role in macular oedema, 
demonstrating that all 3 drugs were useful in decreasing macular 
oedema and improving the vision. However, recurrence may occur 
requiring repeated injections. 
 Its role in proliferative diabetic retinopathy is still under debate. 
While some suggested that their use may limit the extent of laser 
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photocoagulation needed, laser still remains the treatment of choice for 
PDR. These drugs may be used in persistent neovascularisation not 
responding to laser therapy and pre-operatively, to reduce the risk of 
intraoperative haemorrhage. 
 These drugs may be associated with worsening of fibrosis or 
precipitation of tractional retinal detachment. Following anti-VEGF 
injections, a shift in the balance between VEGF and the profibrotic 
factor, CTGF may occur, promoting these changes.  
Steroids 
 Triamcinolone acetonide was the most common steroid used in 
the treatment of diabetic macular oedema. Commonly a dose of 4mg is 
used intravitreally. Although short term results are favourable, 
reflecting an improvement in the visual acuity and reduction in 
macular thickness, recurrences are common, requiring repeat 
injections. This problem has been addressed by Ozurdex, slow release 
devices, as the frequency of injections is reduced to 6 months or less. 
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Other medical therapies 
 Aspirin use did not affect the progression of retinopathy or the 
risk of visual loss according to the ETDRS. Aldose reductase facilitates 
the conversion of glucose to sorbitol. The use of aldose reductase 
inhibitors have not demonstrated any beneficial effects in diabetic 
retinopathy (Sorbinil Retinopathy Trial Research Group, 1993).73 
Lowering of serum lipids was found useful in macular oedema 
associated with hyperlipidemia. 
Vitrectomy 
 The DRVS was conducted to explore the possibilities and 
outcomes of vitrectomy in selected cases. The results suggests that 
early vitrectomy should be considered in eyes with recurrent vitreous 
haemorrhage when it is known from prior examination, that 
fibrovascular proliferation is severe, especially when macular potential 
is good. Additional indications include non-resolving vitreous 
haemorrhage, traction on the disc, peripapillary retina or macula that 
distorts these structures and lead to reduction in vision, tractional 
retinal detachment, combined tractional and retinal detachment and 
neovascularisation of iris with hazy media. 
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SCREENING SCHEDULE - SUGGESTED FOR 
DETAILED OPHTHALMIC EVALUATION OF 
DIABETIC PATIENTS 
Type of diabetes Timing of first eye 
examination 
Follow up interval 
recommended 
Type 1 Within  5  years  of  the  
diagnosis 
Every 1 year 
Type 2 At  the  time  of  
diagnosis 
Every 1 year 
Any type with 
pregnancy 
Before conception or 
in the early first 
trimester 
Every 1-3 months in 
severe NPDR, early 
PDR or high risk PDR  
Every 3-13 months in 
patients with no 
retinopathy or mild or 
moderate NPDR 
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ETDRS RECOMMENDATION FOR FOLLOW-UP 
CATEGORY FOLLOW UP 
No diabetic retinopathy Review in 12 months 
Mild NPDR Review range of 6-12 months, 
depending stability, severity and 
associated systemic features 
Moderate NPDR Review in approximately 6 
months 
Severe NPDR Review in 4 months 
Very severe Review in 2-3 months 
Early PDR Treatment considered according to 
stability, severity and associated 
systemic factors. If the patient is 
not treated, review in 2 months 
High-risk PDR Treatment should be performed 
immediately if possible 
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VITAMIN D AND ITS ROLE IN DIABETIC 
RETINOPATHY 
 An increase in the prevalence of vitamin D deficiency has been 
noted worldwide, along with an increase in the prevalence of diabetes 
mellitus (Lips P et. Al., Gannage-Yared M-H et. Al.).23,24 An increased 
risk of hypovitaminosis D is observed in infants, adolescents and 
lactating women, which may be attributed to increased requirements 
during these periods. People living at higher altitudes may also 
demonstrate lower levels, due to reduced photoconversion of 7-
dehydrocholesterol to previtamin D, a problem which is aggravated in 
winter  months  as  shown  by  Holick  MF  et.  Al.25 Mishal  AA  et.  Al.  
demonstrated that inhabitants of areas with abundant sunlight may also 
have Vitamin D deficiency due to traditional clothing, exposing little 
skin to sunlight, resulting in reduced synthesis of vitamin D.26 A higher 
incidence of vitamin D deficiency is also noted in south Asian and 
black populations, due to increased absorption on UV-B resulting from 
higher levels of skin pigmentation, decreasing vitamin D production. A 
deficient state can manifest, if the requirements are not compensated 
by dietary intake. Wortsman J et. Al. showed that reduced physical 
activity and increased body mass index (BMI) resulting in deposition 
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of biologically inactive vitamin D in adipose tissue may result in 
Vitamin D deficiency.27 Ogunkolade WB et. Al. demonstrated that 
chewing of beetle nut resulting in increased conversion to inactive 
vitamin D metabolite, 24,25 (OH)2D is also known to result in a 
deficient state.28 
 Although Vitamin D is known for its association with calcium 
and phosphorus homeostasis and bone metabolism, recent evidence has 
revealed several unconventional functions of vitamin D including its 
role in respiratory, cardiovascular, infectious and autoimmune diseases 
and cancer.29-38  
 A role of Vitamin D deficiency in the development of both type 
1 and type 2 diabetes mellitus has also been demonstrated.39-46 An 
inverse relationship between fasting blood glucose and 25-OHD 
concentrations was demonstrated by the third National Health and 
Nutrition Examination Survey (NHANES) data in healthy white 
postmenopausal women, and in Mexican American men and women, 
however no such association was seen in non-Hispanic black 
population, suggesting that ethnicity may also have a role in this 
effect.42 The influence of vitamin D on insulin secretion was first 
demonstrated over 3 decades ago by Norman A.W. et. Al. and was 
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further supported by animal studies.47,48 Borrisova  A.M.  et.  Al.  and  
Chiu C.J. et. Al. have now conclusively demonstrated that vitamin D 
influences the pathogenesis of diabetes mellitus through both 
pancreatic insulin secretion49 and insulin sensitivity and thereby affects 
the pathogenesis of the disease.50 Hitman  G.A.  et.  Al.  demonstrated  
that the beta cells possess receptors for the activated hormone 1, 25-
dihydroxyvitamin D3 (1, 25(OH) 2 D3) and vitamin D-dependent 
calcium-binding proteins.51 An improvement in insulin release in 
response to oral glucose load was seen following Vitamin D 
supplementation in one study. It was accompanied by a reduction in 
free fatty acids and an increase in serum calcium.52 Vitamin D may 
influence insulin sensitivity by mediating calcium metabolism and 
regulation of insulin receptor gene.53 It also regulates human 
peroxisome proliferator activated receptor D, which may have an 
important role in insulin sensitivity.54-55  
 Vitamin D has antiangiogenic, antiproliferative, anti-oxidant, 
immunomodulatory and anti-inflammatory functions in several cells. 
These functions are mediated by vitamin D receptors, members of the 
nuclear receptor super family, which is found extensively in the 
retina.56 Albert D.M. et. Al. provided supportive evidence for the role 
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of 1, 25(OH) 2 D3 in inhibiting retinal neovascularization by using a 
mouse model of ischemic retinopathy,57 while Kaur H. et. Al. showed 
that it inhibited endothelial cell proliferation in cell culture studies.58  
 Vitamin  D  may  play  a  role  in  development  and  progression  of  
diabetic retinopathy via inhibition of inflammation, improved insulin 
secretion and sensitivity, antiproliferative effect on endothelial cells, 
anti-angiogenic and anti-proliferative actions. 
  
56 
AIMS AND OBJECTIVES 
AIMS 
 To evaluate the effect of supplementation of Vitamin D in 
delaying the progression, the association of serum 25 hydroxy Vitamin 
D with the level of Diabetic Retinopathy, and its use as a predictor of 
the severity of Diabetic Retinopathy. 
PRIMARY OBJECTIVE  
 To  evaluate  whether  the  oral  supplementation  of  vitamin  D  
delays the progression of Diabetic Retinopathy. 
SECONDARY OBJECTIVE 
 To evaluate the association between serum 25 hydroxy Vitamin 
D and the level of Diabetic Retinopathy 
 To evaluate whether 25 hydroxy Vitamin D level can be used as 
a predictor of the severity of Diabetic Retinopathy. 
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MATERIALS AND METHODS 
SUBJECT SELECTION: 
 40 patients with type 2 diabetes mellitus and diabetic retinopathy 
were included in this prospective, interventional study which was 
carried out at the department of vitreo-retina services, Regional 
Institute of ophthalmology and Government ophthalmic hospital, 
Madras Medical College, Chennai, over a period of 1 year. 
Inclusion criteria: 
· Patients must be aged 18 years and above. 
· Patients with type 2 Diabetes Mellitus who are diagnosed as Non 
Proliferative Diabetic Retinopathy or Proliferative Diabetic 
Retinopathy 
Exclusion criteria:  
· Patients with type 1 Diabetes 
· Patients previously on vitamin D supplementation. 
· Use of medications known to influence mineral metabolism 
including calcitonin, growth hormone, thiazide diuretics, anti-
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convulsants such as Carbamazepine, phenytoin and 
phenobarbitone or excessive doses of vitamin A (> 20,000 
units/day). 
· History of  disorders that  are known to affect  the metabolism of 
Vitamin D and major medical illness including renal failure, 
hepatic dysfunction, and musculoskeletal disorders were 
excluded 
· Serum calcium < 8 or > 11 mg/dL 
· Patients on hormone replacement therapy, steroids or 
testosterone. 
PROCEDURE 
HISTORY: 
 All patients were screened with a detailed history including 
nature & duration of symptoms, duration of exposure to sunlight, diet 
history and history of tobacco chewing or alcohol consumption. 
History of treatment with oral hypoglycaemic agents, insulin, vitamin 
supplements and other drug intake, disorders known to influence 
Vitamin D levels and previous ophthalmic surgery/laser or other 
medical treatment history was also taken. 
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 Patients then underwent a complete systemic and ocular 
examination. 
GENERAL EXAMINATION 
 General vital data like pulse, blood pressure, peripheral pulses 
were  noted.  Height  (in  meters)  and  weight  (in  kgs)  was  recorded  and  
systemic examination of CNS, CVS, RS and abdomen was done. 
OCULAR EXAMINATION 
· Visual acuity was assessed by Snellen’s chart and refractive 
status was noted 
· Anterior segment evaluation with slit lamp biomicroscopy was 
performed 
· Intraocular pressure was measured using Goldmann Applanation 
tonometer 
· Diabetic retinopathy was evaluated by a dilated fundus 
examination using 90D & indirect ophthalmoscopy 
· Fundus photographs were taken for documentation 
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· All patients will underwent Fundus fluorescein angiography and 
OCT to assess maculopathy if present 
· The levels of retinopathy will then be classified as per the 
ETDRS. 
INVESTIGATIONS 
 Fasting blood glucose levels (FBS), Post prandial blood glucose 
levels  (PPBS),  urine  sugar  and  albumin  and  serum  Calcium  were  
measured. Measurement of serum 25 hydroxy Vitamin D and HbA1C 
was be done prior to and following 6 months of oral vitamin D 
supplementation. 
 Twenty patients received daily oral supplementation of 2000 IU 
of  Vitamin  D  for  a  duration  of  6  months,  constituting  the  treatment  
arm, while the other 20 patients served as the control arm.  
FOLLOW UP PROCEDURES/ VISITS  
 Patients were re-examined every month. At each visit visual 
acuity recording, anterior segment examination by slit lamp 
biomicroscopy, tonometry and dilated fundus examination was done. 
Any progression of retinopathy was noted. Fundus photographs were 
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repeated at each visit. Fundus fluorescein angiography was repeated at 
3 months and 6 months. OCT to re-assess maculopathy, was repeated 
at 3 and 6 months, or earlier in selected patients if deemed necessary. 
Fasting and post prandial blood glucose levels (FBS and PPBS) and 
urine sugar and albumin were measured to ensure glycaemia control. 
Compliance with oral Vitamin D supplementation therapy was ensured 
by counting the empty medicine strips at each visit and history of 
Vitamin D toxicity if any was elicited. 
ASSESSMENT OF PARAMETERS 
· The level and severity of diabetic retinopathy 
· Improvement in Best corrected visual acuity (logMAR 
conversion of Snellen’s chart) 
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BIOCHEMICAL ESTIMATION OF VITAMIN D  
IN SERUM 
 In our study, the direct, competitive chemiluminescent 
immunoassay (CLIA) method was used for quantitative estimation of 
25- hydroxy Vitamin D. This is a United States Food and Drug 
Administration (FDA)–approved immunoassay method. This method 
was developed in 2002 and measured total 25-hydroxy vitamin D in 
serum samples. Hepatic metabolism converts Vitamin D3 and D2 to 
25-hydroxyvitamin D. Serum or plasma 25-OH vitamin D levels is the 
best indicator of vitamin D nutritional status. 
PERFORMANCE SPECIFICATIONS 
 The measurement range is from 4 to 150 ng/ml. 
SAMPLE REQUIREMENTS 
· Human serum samples 
· Samples may be collected after an overnight fast, however this is 
not essential 
· Infected and haemolysed samples must be rejected 
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PREPARATION OF SAMPLES 
 At  least  250  µL  of  sample  is  essential  for  the  first  test.  Frozen  
samples must be thawed and mixed thoroughly until a homogeneous 
specimen is obtained. 
STORAGE OF SAMPLES 
 Samples are stored in the frozen state (-20˚C or below) in glass 
or plastic vials without any additives or preservatives. 
REAGENTS 
· Anti 25 OH Vitamin D antibody coated magnetic particles 
· Conjugate used is an isoluminol derivative, in phosphate buffer 
with EDTA, preservatives, surfactants and 10% ethanol 
PRINCIPLE OF THE TEST 
 It is a two step incubation procedure. The initial step involves a 
separation of 25-hydroxy vitamin D from its binding protein, which is 
followed by making it bind to the specific solid phase antibody. This is 
followed by the addition of vitamin D-isoluminol tracer after 10 
minutes. A wash cycle is then used to remove unbound material 
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following the second 10 minute incubation period. Chemiluminescent 
reaction is initiated by adding the starter reagents. The photomultiplier 
detects the light signal, the strength of which is used to determine the 
25-hydroxy vitamin D levels. The light signal, indicated in relative 
light units bears a negative relation with 25 hydroxy vitamin D levels. 
REFERENCE VALUES OF 25 HYDROXY VITAMIN D 
 Deficiency  :  <20 ng/ml 
 Insufficiency : 20 – 30 ng/ml  
 Sufficiency  :  30 - 100 ng/ml  
 Toxicity  :  >150 ng/ml 
STATISTICAL ANALYSIS 
 Data analysis was carried out by the Statistical Package For 
Social Science (SPSS). Quantitative data were presented as means and 
standard deviation and qualitative data were expressed as numbers or 
percent. 
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OBSERVATION AND RESULTS 
 40 patients were enrolled in this study. 20 patients received oral 
Vitamin D supplementation, serving as the case group and the 
remaining 20 patients served as the control group. 
Age distribution 
Table 1. Age distribution of a total of 40 patients in  
the case and control arm. 
Age in years No. of patients – Case group 
No. of patients 
– control group 
Total no. of 
patients 
41-45 1 2 3 (7.5%) 
46-50 1 3 4 (10%) 
51-55 6 6 12 (30%) 
56-60 4 3 7 (17.5%) 
61-65 4 4 8 (20%) 
66-70 3 2 5 (12.5%) 
71-75 1 0 1 (2.5%) 
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Chart 1. Age distribution 
 
 In this study patients between 51-55 years were maximally 
affected (30%). The oldest patient enrolled was 72 years, while the 
youngest patient was 43 years. The mean age at presentation was  
58.85  ±  7.09  years  in  the  case  group  and  56.50  ±  7.72  years  in  the  
control group. 
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Sex distribution 
Table 2.Distribution of males and females 
Sex 
No. of 
patients – 
case group 
No. of 
patients – 
control group 
Total no. of 
patients 
Male 9 12 21 (53.5%) 
Female 11 8 19 (47.5%) 
 
Chart 2. Sex wise distribution 
 
 21 (53.5%) males and 19 (47.5%) females were affected with 
diabetic retinopathy in this study.  
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Laterality and symmetry 
Table 3. Symmetry of involvement of eyes 
 
No. of 
patients – 
case group 
No. of 
patients – 
control group 
Total patients 
Symmetrical 
involvement 
18 19 37 (92.5%) 
Asymmetrical 
involvement 
2 1 3 (7.5%) 
 
Chart 3. Symmetry of involvement of eyes 
 
 All patients enrolled in this study had bilateral disease, however 
the severity of diabetic retinopathy was asymmetrical in 3 patients 
(7.5%). The remaining 37 cases (92.50%) had a bilaterally symmetrical 
presentation of diabetic retinopathy. The age and sex distribution and 
the symmetry of involvement were not significantly different between 
the cases and controls (p>0.05). 
92.50%
7.50%
symmetry of involvement of eyes
Symmetrical involvement
Assymmetrical 
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Severity of diabetic retinopathy at presentation 
Table 4. Classification of patients based on severity of retinopathy 
at presentation 
Severity of 
retinopathy 
No. of 
patients – 
case group 
No. of patients 
– control 
group 
Total 
patients 
Moderate NPDR   5 5 10 
Severe NPDR 5 5 10 
Very severe NPDR 5 5 10 
Early PDR 5 5 10 
 
Table 5.Classification of eyes based on severity of retinopathy at 
presentation 
Severity of 
retinopathy 
No. of eyes in 
case group 
No of eyes in 
control group 
Total no. of 
eyes 
Moderate NPDR   11 11 22 (27.5%) 
Severe NPDR 9 9 18 (22.5%) 
Very severe NPDR 11 10 21 (26.3%) 
Early PDR 9 10 19 (23.8%) 
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Chart 4.Distribution of eyes based on severity of retinopathy 
at presentation 
 
 
 In both the case and control group, 5 patients each were 
diagnosed with moderate NPDR, severe NPDR, very severe NPDR and 
early  PDR.  None  of  the  patients  were  diagnosed  with  mild  NPDR  or  
high-risk PDR at presentation. In patients with asymmetrical disease, 
the eye with increased severity of retinopathy was used to decide the 
level of retinopathy to which the patient must be assigned to.  
 Of the 80 eyes studied, 22 eyes (27.5%) had moderate NPDR, 18 
eyes (22.5%) had severe NPDR, 21 eyes (26.3%) had very severe 
NPDR  and  19  eyes  (23.8%)  had  early  PDR.  The  distribution  of  
severity of retinopathy at presentation was not significantly different 
between the case and control groups by Pearson’s Chi Square test 
(p=0.992). 
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Duration of Diabetes mellitus 
Table 6.duration of diabetes 
Duration of 
diabetes 
(in years) 
No. of patients 
– case group 
No. of patients 
– control group 
Total 
patients 
<5 2 0 2 (5%) 
5-10 4 6 10 (25%) 
10-15 5 8 13 (32.5%) 
15-20 6 4 10 (25%) 
20-25 3 2 5 (12.5%) 
 
Table 7.Distribution of the duration of diabetes according to the 
severity of retinopathy 
Severity of 
retinopathy 
Duration of 
diabetes in cases 
(in years) 
Duration of 
diabetes in 
controls  
(in years) 
p-value 
Moderate NPDR   9.0 +/- 6.48 8.5 +/- 3.87 0.8963 
Severe NPDR 9.0 +/- 3.81 10.50 +/- 4.20 0.592 
Very severe NPDR 12.40 +/- 2.51 10.50 +/- 3.32 0.3587 
Early PDR 17 +/- 4.47 18.25 +/- 3.86 0.6722 
Total  11.6 +/- 5.52 11.74 +/- 5.14 0.976 
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Chart 5.Duration of diabetes 
 
 The duration of diabetes was taken as the interval between the 
first diagnosis of diabetes mellitus by health personnel and the present 
study period. A majority of patients (32.5 %) had duration of diabetes 
between 10-15 years, 25% of patients had duration between 5-10 and 
15-20 years, 12.5% had a duration between 20-25 years and the least 
number of patients had a duration of less than 5 years (5%). 
 Patients with early PDR had the longest duration, with a mean of 
17 years and 18.25 years in the case and control groups respectively. 
On the other hand, patients with moderate NPDR showed a mean of 9 
years and 8.5 years in the case and control groups respectively, being 
the least.  
 The mean duration of diabetes in the case and control groups 
was 11.6 years and 11.74 years respectively.  
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Distribution of maculopathy 
Table 8.Distribution of maculopathy 
Maculopathy No. of eyes - 
cases 
No. of eyes – 
controls 
Total eyes 
Present 27 (67.5%) 30 (75%) 57 (71.25%) 
Absent 13 (32.5%) 10 (25%) 23 (28.75%) 
 
Chart 6.Distribution of maculopathy 
 
 A total of 57 eyes (71.25%) had associated maculopathy with 
features of diabetic retinopathy. The mean CMT at baseline was 250 ± 
59.67 microns in the cases and 252.80 ± 54.65 microns in the controls. 
The  cases  and  controls  did  not  differ  significantly  in  the  duration  of  
diabetes, occurrence of maculopathy or the mean CMT at baseline. 
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Best Corrected Visual Acuity at baseline 
Table 9.BCVA at baseline 
Visual Acuity Case group Control group 
No.of eyes % No.of eyes % 
3/60 - 6/60  6 15 6 15 
6/36 – 6/24 8 20 9 22.5 
6/18 – 6/12  19 47.5 17 42.5 
6/9 – 6/6  7 17.5 8 20 
 
Chart 7.BCVA at baseline 
 
 After logMAR conversion, the mean BCVA was found to be 
0.5085 ± 0.33059 in the cases and 0.5250 ± 0.33429 in the controls 
which was not found to be significantly different, with a two-tailed p-
value of 0.828 by unpaired t-test. 
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Treatment of diabetes mellitus 
Table 10.Treatment of diabetes 
Treatment of 
Diabetes 
No. of patients-
Case group 
No. of patients 
– control 
group 
Total no. of 
patients 
Insulin 10 9 19 (47.5%) 
Oral hypoglycaemic 
agents (OHA) 
9 9 18 (45%) 
Insulin + OHA 1 2 3 (7.5%) 
 
 19 patients (47.5%) were on insulin therapy, 18 patients (45%) 
were on oral hypoglycaemic agents (OHAs) and 3 patients (7.5%) were 
on treatment with Insulin and OHAs. 
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Table 11.Distribution of the treatment of diabetes according to the 
severity of retinopathy 
Treatment of diabetes 
No. of 
patients-
Case 
group 
No. of 
patients – 
control 
group 
Total 
no. of 
patients 
Moderate 
NPDR   
OHA 5 5 10 
Severe NPDR OHA 4 4 8 
Insulin 1 1 2 
Very severe 
NPDR 
Insulin 4 4 8 
Insulin + OHA  1 1 2 
Early PDR Insulin 5 4 9 
 Insulin + OHA  0 1 1 
 
 While  a  majority  of  patients  with  early  PDR,  very  severe  and  
severe NPDR were receiving insulin therapy, all patients diagnosed 
with moderate NPDR were receiving treatment with OHAs alone. 
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Treatment of retinopathy 
Table 12.Treatment of retinopathy 
Treatment of retinopathy No. of eyes – 
cases 
No. of eyes - 
controls 
Grid laser photocoagulation 30 30 
Pan-retinal  
photocoagulation 
29 31 
 
Chart 8.Distribution of retinopathy 
 
 Patients in the case as well as control group continued to receive 
laser treatment in the form of pan-retinal photocoagulation or grid 
photocoagulation during the course of the study. The number of eyes 
receiving grid laser photocoagulation was 30 patients each in the case 
and control groups, while those receiving pan-retinal photocoagulation 
were 29 and 31 patients respectively in the case and control groups.  
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Associated systemic diseases 
Table 13.distribution of associated hypertension 
 No. of patients with hypertension Percentage 
Case group 6 15% 
Control group 5 12.5% 
   
 15% of cases and 12.5% of controls had associated systemic 
hypertension. None of the patients enrolled in the study had other 
systemic diseases. The groups did not differ significantly in the 
treatment of diabetes mellitus or retinopathy or associated systemic 
diseases (p-value > 0.05). 
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HbA1c levels at baseline 
Table 14.Distribution of HbA1c levels according to the  
severity of retinopathy 
Severity of 
retinopathy 
Mean 
(in %) 
Standard 
deviation 
Mean 
(in %) 
Standard 
deviation P value 
Moderate 
NPDR   7.140 0.270 7.160 0.288 
0.9126 
Severe NPDR 7.540 0.055 7.520 0.084 0.6666 
Very severe 
NPDR 7.880 0.084 7.9 0.082 
0.7294 
Early PDR 8.3 0.1 8.3 0.115 1.0 
Total  7.715 0.460 7.715 0.459 1.0 
 
Table 15.Distribution of HbA1c levels 
Serum HbA1c 
levels 
No. of patients 
Moderate 
NPDR 
Severe 
NPDR 
Very 
severe 
NPDR 
Early 
PDR 
Total 
patients 
6.0%-7.0% 4 0 0 0 4 (10%) 
7.0%-8.0% 6 10 8 0 24 (60%) 
8.0%-10% 0 0 2 10 12 (30%) 
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Chart 9.Distribution of HbA1c levels according to severity of 
retinopathy 
 
 
 
 The mean serum HbA1c levels were 7.715 ± 0.460% in cases 
and 7.715 ± 0.459% in controls, which was not found to be 
significantly different (two-tailed p value=1.0 by unpaired t-test). The 
levels of serum HbA1c were highest in patients with early PDR in both 
cases and controls and progressively decreased with increasing severity 
of retinopathy, being lowest in patients with moderate NPDR.  
 Of the 40 patients enrolled in the study, a majority (60%) of the 
patients demonstrated fair gylcaemic control (serum HbA1c = 7.0%-
8.0%), 30% of the patients showed unsatisfactory control (serum 
HbA1c = 8.0%-10.0%) and the remain 10% of patients demonstrated 
good glycaemic control (serum HbA1c = 6.0%-7.0%) 
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Serum FBS levels 
Table 16.FBS Levels in diabetic retinopathy 
Severity of 
retinopathy 
FBS levels 
Mean 
(in 
mg/dl) 
Standard 
deviation 
Mean 
(in 
mg/dl) 
Standard 
deviation P value 
Moderate 
NPDR 131.4 8.96 131.25 11.44 
0.9830 
Severe NPDR 146.8 6.42 147.2 10.43 0.9436 
Very severe 
NPDR 154.6 4.04 153.6 3.71 
0.6943 
Early PDR 171.2 7.09 170.4 8.11 0.8722 
Total  151.0 16.0 150.8 16.14 0.9688 
 
Chart10.Baseline serum FBS levels in diabetic retinopathy 
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 The mean serum fasting blood sugar levels were 151 ± 16 mg/dl 
and 150 ± 16.14 mg/dl in the cases and control groups respectively, 
which did not differ significantly (two-tailed p value=0.9688 by 
unpaired t-test). The levels of serum FBS were highest in patients with 
early PDR in both cases and controls and progressively decreased, 
being lowest in patients with moderate NPDR. The levels of both 
HbA1c and FBS did not differ significantly between cases and controls 
having moderate, severe, very severe NPDR and early PDR (p > 0.05). 
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Serum 25 hydroxy Vitamin D levels at baseline 
Table 17.Distribution of baseline serum 25 hydroxy vitamin D 
levels 
Serum 25 
hydroxy 
Vitamin D 
levels (ng/ml) 
No. of patients 
Moderate 
NPDR 
Severe 
NPDR 
Very 
severe 
NPDR 
Early 
PDR 
Total 
patients 
<20 8 8 9 10 35 
(87.5%) 
20-30 1 1 1 0 3 (7.5%) 
30-100 1 1 0 0 2 (5%) 
>100 0 0 0 0 0 
 
Table 18. Distribution of baseline serum 25 hydroxy vitamin D 
levels according to severity of retinopathy 
 
Severity of 
retinopathy 
Mean 
Vitamin 
D levels 
(ng/ml) 
Standard 
deviation 
Minimum 
Vitamin D 
levels (in 
ng/ml) 
Maximum 
vitamin D 
level (in 
ng/ml) 
Moderate NPDR   27.573 6.0525 18.8 42.5 
Severe NPDR 22.518 3.6956 18.3 32.3 
Very severe 
NPDR 17.557 1.7105 15.8 21.1 
Early PDR 12.131 2.7112 9.1 17.7 
Total  19.945 6.9074 9.1 42.5 
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Chart 11.Mean 25 hydroxy Vitamin D levels at baseline according 
to severity of retinopathy 
 
 A total  of  35 patients  (87.5%) enrolled in the study were found 
to have Vitamin D deficiency (serum 25 hydroxy vitamin D: < 20 
ng/ml), 3 patients (7.5%) were found to have Vitamin D insufficiency 
(serum 25 hydroxy vitamin D : 20-30 ng/ml) and 2 patients (5%) were 
found to have normal Vitamin D levels. 
 By  One  way  ANOVA  with  Post  Hoc  tests  and  Tukey  HSD,  a  
highly significant p value of less than 0.001 was obtained, indicating 
that the levels of serum 25 hydroxy Vitamin D measured in the 40 
patients at baseline were significantly lowered as the severity of 
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retinopathy increased from moderate NPDR to early PDR. The patients 
with moderate NPDR had a mean value of serum 25 hydroxy vitamin 
D of 27.573 ng/ml, which decreased to 22.518 ng/ml and 17.557 ng/ml 
in patients with severe and very severe NPDR respectively and patients 
with early PDR had the lowest value of serum 25 hydroxy vitamin D of 
19.945 ng/ml.  
 Pearson correlation test, showed a two-tailed significance of - 
0.841, indicating a strongly negative correlation between serum 25 
hydroxy Vitamin D levels with the severity of diabetic retinopathy as 
documented at baseline in all 40 patients. Hence as the serum levels of 
25 hydroxy Vitamin D decreased, the severity of diabetic retinopathy 
was found to increase. 
 The mean serum 25 hydroxy Vitamin D levels were 19.775 ± 
5.663 ng/ml and 20.115 ± 8.101 ng/ml in the case and control groups 
respectively at presentation and did not differ significantly between the 
two groups, having a two-tailed p value of 0.8793 by the unpaired t-
test. 
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Serum 25 hydroxy Vitamin D levels at 6 months 
Chart12.Serum 25 hydroxy Vitamin D at baseline and 6 months 
 
 
 The mean serum 25 hydroxy Vitamin D levels were 42.4930 ± 
9.9332 ng/ml and 20.1305 ± 1.7346 ng/ml in the case and control 
group respectively at the end of 6 months, which was significantly 
higher in the case group following 6 months of oral supplementation 
than the control group. A two-tailed p value of 0.8793 by the unpaired 
t-test was obtained. 
 The mean serum 25 hydroxy Vitamin D levels were 20.1150 ± 
8.1012 ng/ml and 20.1305 ± 7.7575 ng/ml in the control group at 
baseline and at 6 months respectively, showing a no significant 
difference with a two-tailed p value of 0.9585 by the paired t-test. 
0
10
20
30
40
50
Baseline
6 months
19.78
42.49
20.12 20.13
M
ea
n 
25
 (O
H
) V
ita
m
in
 D
le
ve
l 
(in
 n
g/
m
l)
Case group
control group
87 
Table 19.Distribution of serum 25 hydroxy Vitamin D levels at 6 
months in cases 
Serum 25 hydroxy Vitamin 
D3 levels (ng/ml) in cases at 
6 months 
No. of patients percentage 
<20 0 0 
20-30 4 10% 
30-100 16 80% 
>100 0 0 
 
 Following 6 months of oral supplementation of Vitamin D, 80% 
cases attained normal serum 25 hydroxy vitamin D levels (30-100 
ng/ml), 10% patients remained insufficient (20-30 ng/ml) and none of 
the patients remained deficient (<20 ng/ml). None of the cases attained 
toxic serum levels of  25 hydroxy vitamin D (>100 ng/mg).  
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Severity of retinopathy – at 1 month follow up 
Table 20.Severity distribution of retinopathy at 1 month 
Severity of 
retinopathy 
at 1 month 
No. of eyes 
in case 
group 
Percentage 
in case 
group 
No of eyes 
in control 
group 
Percentage 
in control 
group 
Moderate 
NPDR   
11 27.5% 11 27.5% 
Severe NPDR 9 22.5% 9 22.5% 
Very severe 
NPDR 
11 27.5% 10 25% 
Early PDR 9 22.5% 10 25% 
 
Chart 13.Severity distribution at 1 month 
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 At 1 month follow up, 27.5% of eyes in both the case and 
control groups were found to have moderate NPDR and 22.5% eyes in 
both groups had severe NPDR. 27.5% of eyes among the cases had 
very severe NPDR, compared to 25% of controls and 22.5% of eyes in 
the case group had early PDR compared to 25% of eyes of controls. 
The severity of diabetic retinopathy noted at 1 month follow up did not 
differ significantly between the cases and controls (2-sided p=0.992 
according to Pearson Chi-Square test). 
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Severity of retinopathy – at 3 months follow-up 
Table 21.Severity distribution of retinopathy at 3 months 
Severity of 
retinopathy 
at 3 month 
No. of eyes 
in case 
group 
Percentage 
in case 
group 
No of eyes 
in control 
group 
Percentage 
in control 
group 
Moderate 
NPDR   
11 27.5% 11 27.5% 
Severe NPDR 9 22.5% 9 22.5% 
Very severe 
NPDR 
11 27.5% 10 25% 
Early PDR 9 22.5% 2 5% 
High-risk 
PDR 
0 0 8 20% 
 
Chart 14.Severity distribution at 3 months 
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 At 3 months, there was no progression noted in the patients 
found to have moderate, severe and very severe NPDR in both groups, 
with 27.5% of the eyes of cases and controls having moderate NPDR 
and 22.5% of the eyes patients in both groups having severe NPDR. 
27.5% of cases had very severe NPDR, compared to 25% of controls 
and 22.5% of cases had early PDR compared to 25% of controls. 
27.5% and 25% of the eyes of cases and controls respectively were 
found to have very severe NPDR. 22.5% eyes with early PDR in the 
case group did not progress at 3 months. However in the control group 
8 eyes (20%) with early PDR at 1 month progressed to high risk PDR. 
This progression from early PDR to high-risk PDR in the control 
group, compared to no such progression among the cases was found to 
be statistically significant (2-sided p=0.014 according to Pearson Chi-
Square test). 
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Severity of retinopathy - at 6 months 
Table 22. Severity distribution of retinopathy at 6 months 
Severity of 
retinopathy 
at 6 month 
No. of eyes 
in case 
group 
Percentage 
in case 
group 
No of eyes 
in control 
group 
Percentage 
in control 
group 
Moderate 
NPDR   
11 27.5% 11 27.5% 
Severe NPDR 8 20% 5 12.5% 
Very severe 
NPDR 
10 25% 1 2.5% 
Early PDR 7 17.5% 12 30% 
High-risk 
PDR 
4 10% 11 27.5% 
 
Chart 15. Severity distribution at 6 months 
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 At 6 months, none of the eyes with moderate NPDR progressed 
in both groups, with 27.5% of the eyes of cases and controls having 
moderate NPDR. Severe NPDR was found in 20% and 12.5 % of eyes 
of cases and controls respectively. Very severe NPDR was found in 
25% of eyes of cases and 2.5% of eyes of controls. 17.5% and 30% of 
eyes of the cases and controls were found to have early PDR. High risk 
PDR  had  developed  in  10%  of  eyes  of  cases  and  27.5%  of  eyes  of  
controls. Hence at 6 months majority of eyes of cases showed 
moderate NPDR while majority of eyes of controls showed early PDR.   
 Hence at 6 months, eyes with severe, very severe NPDR and 
early PDR were found to have progressed in both groups, however the 
progression was significantly greater in cases then in controls (2-sided 
p=0.013 according to Pearson Chi-Square test). 
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Maculopathy at 6months 
Table 23.Distribution of maculopathy at 6 months 
maculopathy No. of eyes - cases 
No. of eyes - 
controls Total eyes 
Present 9 10 19 
Absent 31 30 61 
 
 The mean CMT was 194.67 ± 50.67 microns in cases and 197.08 
± 34.40 microns in controls which did not differ significantly between 
the two groups at the end of 6 months (p>0.05). 
 The mean CMT was found to decrease significantly in both the 
cases and controls at the end of 6 months with a two-tailed p value = 
0.0001 by paired t-test in both groups. 
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BCVA at 6 month 
Table24.BCVA at 6 months 
Visual Acuity 
Case group Control group 
No.of eyes % No.of eyes % 
3/60 - 6/60  5 12.5 3 7.5 
6/36 – 6/24  3 7.5 4 10 
6/18 – 6/12  23 57.5 20 50 
6/9 – 6/6  9 22.5 13 32.5 
 
Chart 16.BCVA at 6 months 
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 After logMAR conversion, the mean best corrected visual acuity 
was found to be 0.4265 ± 0.3311 in the cases and 0.3750 ± 0.2507 in 
the controls which was not found to be significantly different, with a 
two-tailed p-value of 0.435 by unpaired t-test. 
 After logMAR conversion at 6 months, the mean best corrected 
visual acuity improved significantly from 0.5085 ± 0.3360 at baseline 
to 0.4265 ± 0.3311  at  6  months  in  the  40  eyes  enrolled  in  the  case  
group (two-tailed p value=0.0324 by paired t-test). A significant 
improvement was also found in the 40 eyes of controls from a mean 
BCVA of 0.5250 ± 0.3443 at baseline to 0.3750 ± 0.2507 at 6 months 
(two-tailed p value=0.0008 by paired t-test).   
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DISCUSSION 
 Diabetic retinopathy remains one of the leading causes of visual 
loss in the working-age people. After duration of diabetes exceeding 15 
years, it affects three out of four diabetic patients.  
 In our study 75% of patients belonged to the 6th and 7th decades 
of life. This may be due to the fact that prevalence of systemic diseases 
such as diabetes and hence its resulting microvascular complications, 
increases with increasing age. The youngest patient enrolled was 43 
years and the oldest was 72 years. Previous studies revealed a similar 
age distribution. (Daniel M.Taylor et al. Survey ophthalmology).59 
 In our study, 53.5% males and 47.5% females were affected 
with diabetic retinopathy. Although an increased percentage of males 
were found to be affected, no significant male preponderance was 
observed. This finding was consistent with previous studies.14.15 
 All patients enrolled in this study had bilateral disease, however 
the severity of diabetic retinopathy was asymmetrical in 7.5% of 
patients. 
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 Among the 80 eyes studies, 27.5% had moderate NPDR, 
22.5% had severe NPDR, 26.3% had very severe NPDR and 23.8% 
had early PDR. 71.5% eyes had maculopathy associated with 
retinopathy. In the Oman study, 60% of the eyes had NPDR, 18% had 
PDR and 24% of eyes had associated maculopathy. This increased 
incidence in our study, could be attributed to the late presentation of 
diabetic patients for ophthalmological screening due to decreased 
awareness.60 
 We found that a majority of 32.5 % of patients with retinopathy 
had duration of diabetes between 10-15 years. As expected, in patients 
with a greater duration of diabetes, an increased severity of retinopathy 
was observed. Patients with early PDR had the longest duration, with 
almost all cases having duration of more than 10 years. On the other 
hand, patients with moderate NPDR showed duration of less than 10 
years. These findings were consistent with the Oman study and the 
study by Jernald B Alguere.60,61 
 In our study, baseline mean serum HbA1c levels were 7.715 +/- 
0.460% in cases and 7.715 +/- 0.459% in controls. The baseline mean 
serum fasting blood sugar levels were 151 +/- 16 mg/dl and 150 +/- 
16.14 mg/dl in the cases and control groups respectively. The levels of 
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serum HbA1c and fasting blood glucose were highest in patients with 
early PDR progressively decreased, being lowest in patients with 
moderate NPDR, findings that were supported by the DCCT study and 
the study by Kroc Collaborative Study Group.62-66 
 87.5% of patients enrolled in the study were found to have 
Vitamin D deficiency (serum 25 hydroxy vitamin D: < 20 ng/ml), 
7.5% were found to have Vitamin D insufficiency (serum 25 hydroxy 
vitamin D : 20-30 ng/ml) and 2 patients 5% were found to have normal 
Vitamin D levels. 
 The levels of serum 25 hydroxy Vitamin D measured in the 40 
patients at baseline were significantly lower as the severity of 
retinopathy increased from moderate NPDR to early PDR. The patients 
with moderate NPDR had a mean value of serum 25 hydroxy vitamin 
D of 27.573 ng/ml, which decreased to 22.518 ng/ml and 17.557 ng/ml 
in patients with severe and very severe NPDR respectively and patients 
with early PDR had the lowest value of 19.945 ng/ml. Hence our study 
demonstrated an inverse relationship between the severity of diabetic 
retinopathy and serum 25 hydroxy Vitamin D levels, findings which 
were supported by several other studies.  
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 A strongly negative correlation between serum 25 hydroxy 
Vitamin D levels and severity of diabetic retinopathy was documented, 
suggesting that neovascularization in the retina may involve a decrease 
in serum 25(OH) D concentrations in patients with diabetic 
retinopathy. Hence, low serum levels of 25 (OH) D may have an 
association with uncontrolled angiogenesis and the progression of DR 
as demonstrated by Aksoy H. et. Al.67 
 A cross-sectional study of type 2 diabetic patients conducted by 
Suzuki A et. Al. showed a significant association between the 
existence of proliferative retinopathy and a decrease in 25(OH) D.68 
Investigators found a decrease in 25(OH) D according to the number of 
microvascular complications present. These findings were also 
supported by a study conducted by Joergensen C et. Al.69 A clinic-
based, cross-sectional study by Paynes et. Al. to assess the relationship 
between vitamin D status and diabetic retinopathy concluded that 
diabetic subjects, especially those with PDR, have lowered 25(OH) D 
levels than those without diabetes.70 Our findings were also in 
agreement with the study done by Hulya et al. who demonstrated an 
inverse relationship between the severity of the retinopathy and retinal 
neovascularisation with serum 1,25(OH) 2 D3 concentrations, levels 
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being  the  lowest  in  PDR  and  the  highest  in  diabetic  patients  without  
retinopathy. 
 In order to evaluate whether Vitamin D supplementation delayed 
the progression of diabetic retinopathy, 40 eyes each in the case and 
control group were followed up, on a monthly basis for 6 months and 
the severity of retinopathy was documented. The case and control 
groups did not differ significantly in the age, sex distribution, duration 
of diabetes, associated systemic diseases such as hypertension, 
treatment modalities of diabetes and retinopathy, severity distribution 
of retinopathy, associated maculopathy and serum HbA1c, fasting 
blood glucose and 25 hydroxy vitamin D.  
 The mean serum 25 hydroxy Vitamin D level of 42.4930 ng/ml 
was attained in the cases following 6 months of oral supplementation, 
suggesting that this dose used was adequate for normalisation of serum 
vitamin D levels according to our study. The mean levels remained 
deficient (20.1305 ng/ml) in the controls at the end of 6 months.  
 There was a wide variation in the duration, dosage and mode of 
supplementation used in previous studies. The present “no observed 
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adverse effect limit” of 2000 IU daily has been found to be too low at 
least by 5-fold.71 
 In human beings, serum 25 hydroxy vitamin D has been found to 
have  a  half  life  of  about  1  month.  A  minimum  of  4  half  lives  are  
required before a drug attains an equilibrium concentration. However 
the concentrations of serum 25 hydroxy vitamin D have been found to 
change depending on its synthesis and clearance. Hence it has been 
suggested that it attains a stable serum concentration much earlier. 
Moreover Davie MW et. Al. demonstrated that 25 hydroxy vitamin D 
attains a plateau level by 1 month of supplementation. Hence an oral 
dose of 2000 IU daily was used for 6 months supplementation in our 
study.  
 At 1 month follow up, none of the 80 eyes showed progression. 
At 3 months, there was no progression noted in the patients with 
moderate, severe and very severe NPDR in both groups. However a 
significantly increased progression from early PDR to high-risk PDR 
was found in the control group. While none of the eyes with early PDR 
in the case group were found to have progressed, 8 eyes (20%) with 
early PDR in the control group at 1 month had progressed to high risk 
PDR.  
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 At 6 months, none of the eyes with moderate NPDR progressed 
in both groups, however eyes with severe, very severe NPDR and early 
PDR were found to have progressed in both groups, this progression 
being significantly greater in controls then cases. Severe NPDR was 
found  in  20%  and  12.5  %  of  eyes  of  cases  and  controls  respectively.  
Very  severe  NPDR  was  found  in  25%  of  eyes  of  cases  and  2.5%  of  
eyes of controls. 17.5% and 30% of eyes of the cases and controls were 
found to have early PDR. High risk PDR had developed in 10% of 
eyes of cases and 27.5% of eyes of controls. 
 The BCVA and maculopathy was found to improve significantly 
from baseline in both cases and controls, however no difference in 
BCVA or maculopathy was observed between the two groups at 6 
months. This suggests that no additional improvement in BCVA or 
maculopathy was obtained with vitamin D supplementation, over and 
above the recommended treatment for diabetic retinopathy. 
None of the cases developed any complications relating to 
Vitamin D toxicity at this dosage recommendation.  
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SUMMARY 
 40 patients with type 2 diabetes mellitus and diabetic retinopathy 
were included in this prospective, interventional study which was 
carried out at the department of vitreo-retina services, Regional 
Institute of ophthalmology and Government ophthalmic hospital, 
Madras Medical College, Chennai, over a period of 1 year. 
 The aim was to evaluate the effect of supplementation of 
Vitamin D in delaying the progression of diabetic retinopathy, to study 
the  association  of  serum  25  hydroxy  Vitamin  D  with  the  level  of  
Diabetic Retinopathy, and its use as a predictor of the severity of 
Diabetic Retinopathy. 
 20  patients  received  daily  oral  supplementation  of  2000  IU  of  
Vitamin D for a period of 6 months constituting the case arm, while the 
other 20 patients served as the control arm.  
75%  of  patients  enrolled  in  the  study  belonged  to  the  6th and  7th 
decades of life. 53.5% males and 47.5% females were affected with 
diabetic retinopathy in this study. 
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 Among the 80 eyes studies, 27.5% had moderate NPDR, 22.5% 
had severe NPDR, 26.3% had very severe NPDR and 23.8% had early 
PDR. 71.5% eyes had maculopathy associated with retinopathy. 
 Our study demonstrated an inverse relationship between the 
severity of diabetic retinopathy and serum 25 hydroxy Vitamin D 
levels at baseline. Patients with moderate NPDR had a mean serum 25 
hydroxy vitamin D of 27.573 ng/ml, which decreased to 22.518 ng/ml 
and 17.557 ng/ml in patients with severe and very severe NPDR 
respectively  and  patients  with  early  PDR  had  the  lowest  value  of  
19.945 ng/ml. 
 The mean serum 25 hydroxy Vitamin D level of 42.4930 ng/ml 
was attained in the cases following 6 months of oral supplementation. 
 At 1 month follow up, none of the 80 eyes showed progression. 
At 3 months, there was no progression noted in the patients with 
moderate, severe and very severe NPDR in both groups. 8 eyes (20%) 
with early PDR in the control group at 1 month had progressed to high 
risk PDR. No such progression was noted in cases with early PDR. 
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 At 6 months, none of the eyes with moderate NPDR progressed 
in both groups, however eyes with severe, very severe NPDR and early 
PDR were found to have progressed in both groups, this progression 
being significantly greater in controls then cases.  
 Severe  NPDR  was  found  in  20%  and  12.5  %  of  eyes  of  cases  
and  controls  respectively.  Very  severe  NPDR  was  found  in  25%  of  
eyes of cases and 2.5% of eyes of controls. 17.5% and 30% of eyes of 
the cases and controls  were found to have early PDR. High risk PDR 
had developed in 10% of eyes of cases and 27.5% of eyes of controls.  
 The BCVA and maculopathy was found to improve significantly 
from baseline in both cases and controls, however no difference in 
BCVA or maculopathy between the two groups at 6 months.  
 None of the cases developed any complications relating to 
Vitamin D toxicity. 
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LIMITATIONS OF THE STUDY 
 Limitations  of  our  study  were  the  small  sample  size  and  short  
follow up period of 6 months. Larger study group is necessary to 
quantify the actual magnitude of benefit of vitamin D supplementation 
in diabetic retinopathy. Longer follow up is necessary to document 
whether the beneficial effect of such supplementation is seen in mild 
and moderate NPDR as well. 
  
108 
CONCLUSION 
 From  the  results  of  our  study  we  can  conclude  that  oral  
supplementation of Vitamin D in addition to the recommended 
treatment with photocoagulation, delays the progression of severe, very 
severe and early PDR.  
 This beneficial effect was observed with an oral dose of 2000 IU 
daily for 6 months. No toxicity of Vitamin D was noted at this dosage.   
 An inverse relation between the level of Serum 25 hydroxy 
vitamin D concentrations and the severity of diabetic retinopathy was 
noted. 
 Our  study  demonstrated  that  low levels  of  vitamin  D may be  a  
risk marker of development or progression of diabetic retinopathy. It 
may be advisable to conduct ophthalmologic examination at increased 
frequency in diabetics whose serum 25 hydroxy vitamin D 
concentrations are diminished. Serum 25 hydroxy vitamin D 
concentrations could become a useful biochemical marker to predict 
the severity of DR in patients with diabetes mellitus in the future. 
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 No additional improvement in BCVA or maculopathy was 
obtained with vitamin D supplementation, over and above the 
recommended treatment for diabetic retinopathy. 
 Further studies with a longer follow-up period and larger sample 
size are warranted to assess the association between serum 25 hydroxy 
vitamin D levels and diabetic retinopathy and the efficacy and safety of 
vitamin D supplementation in delaying the progression of diabetic 
retinopathy. 
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PROFORMA  
TITLE: “A clinical study of Vitamin D supplementation in Diabetic 
Retinopathy patients with type 2 Diabetes Mellitus” 
NAME:  
AGE: 
(Identify certificate having DOB/ Educational certificate/ Marital status 
and family history/ Appearance)  
SEX: 
 
DATE: 
 
HOSPITAL No.: 
OCCUPATION: 
ADDRESS: 
CONTACT No.: 
UNIT: 
 
CLINICAL HISTORY 
History of presenting complaints: 
H/O defective vision in one/both eyes 
H/O diminution of vision in one/both eyes: 
· Gradual/sudden 
· Mild/moderate/severe 
· Duration 
H/O associated eye pain, redness, watering, photophobia, 
metamorphopsia, coloured halos, positive scotoma 
H/O wearing glasses in the past (if so – refractive status) 
H/O any previous ocular surgeries 
H/O any ocular trauma  
H/O drug intake 
H/O any multivitamin intake 
 
PAST HISTORY: 
H/O diabetes mellitus  
Type of diabetes: IDDM/NIDDM 
· Duration 
· Age of onset of diabetes 
· Treatment for diabetes – OHA/insulin/both 
· Whether diabetes is under control or not 
· Severity of diabetic retinopathy 
· Treatment for diabetic retinopathy: PRP/Grid/Focal (no. Of 
sittings) 
H/O any other systemic diseases: TB/asthma/Ischemic heart 
disease/nephropathy/Hypertension (duration, treatment taken, whether it 
is under control or not) 
PERSONAL HISTORY:  
Diet 
H/O tobacco intake (smoking beedi/cigarette) 
H/O alcohol intake 
Amount of outdoor exposure to sunlight 
Education 
Marital status 
 
GENERAL EXAMINATION 
Height (in meters) 
Weight (in kgs) 
BMI 
Nutritional status 
Blood pressure 
Skin and Musculoskeletal system 
CVS 
CNS 
RS 
Abdomen 
  
OCULAR EXAMINATION 
      RE       LE 
Visual acuity 
UCVA/BCVA/VA with PH 
EOM 
Lids 
Conjunctiva 
Cornea 
Iris 
Pupil 
Anterior chamber 
Lens 
Intraocular pressure 
Duct 
Refractive status 
Fundus: Distant direct, Direct, IDO and 90D- 
· Media 
· Disc  
· Vessels:  
o AV ratio 
o Venous changes-dilatation, beading, looping. segmentation  
o Arteriolar narrowing, obliteration 
· Retinal background – microaneurysms, dot and blot or flame 
shaped hemorrhages, hard exudates, soft exudates, retinal edema, 
IRMA 
· Macula – hemorrhage, edema, exudates 
· NVD/NVE 
· Tractional retinal detachment 
Fundus photo 
FFA- 
· leakage 
· Areas of capillary non perfusion 
· Neovascularisation 
· IRMA 
OCT- macular thickness 
Diagnosis 
Colour vision 
Fields 
 
IVESTIGATION: 
For Serum 25 hydroxy Vitamin D levels: 
· Date and time of sample collection 
· Result 
· Methodology of 25 hydroxy vitamin D estimation 
· Follow up visits 
· Compliance: by counting empty drug strips 
· Evidence of Vitamin D toxicity   
FBS/PPBS 
Urine albumin and sugar 
Serum cholesterol 
Serum Calcium 
Serum HbA1c 
 
FOLLOW UP VISITS 
· BCVA/IOP/Anterior segment/Fundus/Fundus photography 
o 1month 
o 2 months 
· 3 months- BCVA/IOP/Anterior segment/Fundus/Fundus 
photography/FFA/OCT 
· BCVA/IOP/Anterior segment/Fundus/Fundus photography 
o 4 months 
o 5 months 
· 6 months- BCVA/IOP/Anterior segment/Fundus/Fundus 
photography/FFA/OCT 
KEY TO MASTER CHART 
 
 
Sr. No.: Serial number 
 
Sex:  
 
 M– Male 
 F – Female 
 
Treatment group: 
 
 1:Case group 
 2:Control group 
 
Eye affected 
 
 RE:Right eye 
 LE:Left eye 
 BE:Both eyes 
 NIL:None of the eyes 
 
Diagnosis at presentation/1m/3m/6m/FFAdiagnosis: 
 
 1:Moderate NPDR 
 2:Severe NPDR 
 3:Very severe NPDR 
 4:Early PDR 
 5:High-Risk PDR 
 
CSME:Clinically significant macular oedema 
CMT:Central macular thickness (in microns) 
OCT:Optical coherence tomography 
BCVA:Best corrected visual acuity 
IOP:Intraocular pressure 
FFA:Fundus fluorescein angiography 
 
25(OH)Vit D: 25 hydroxy Vitamin D levels (ng/ml) 
HbA1c:Glycosylated haemoglobin (in percentage) 
FBS:Fasting blood glucose (in mg/dl) 
 
Treatment of DM: 
 
 1:Insulin 
 2:Oral Hypoglycaemic agents 
 3:Both Insulin and Oral hypoglycaemic agents 
 
Associated systemic diseases: 
 1:Present 
 2:Absent 
 
PRP:Panretinal photocoagulation 
GRID:Grid laser photocoagulation 
 
1m:1month 
3m:3 months 
6m:6 months  
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1 Ramaswami       60 M 28168 20 1 4 4 BE 339 280 6/36 6/24 16 18 4 4 BE 9.6 8.4 181 1 1 BE GRID PRP 26.61 7.8 6/24 6/18 4 4 BE 6/24 6/18 4 4 BE 329 261 6/60 6/18 5 5 RE 310 185
2 James Isaac     64 M 18406 15 1 1 1 BE 318 243 6/36 6/18 14 14 1 1 BE 25.8 7.3 138 2 2 BE GRID 52.54 6.8 6/36 6/18 1 1 BE 6/18 6/18 1 1 NIL 176 179 6/9 6/18 1 1 NIL 173 179
3 Lakshmi         55 F 17150 15 1 1 2 LE 178 239 6/12 6/18 18 14 1 2 LE 23.2 7.5 156 2 2 LE GRID PRP 50.43 7.1 6/12 6/18 1 2 NIL 6/12 6/18 1 2 NIL 181 177 6/12 6/18 1 2 NIL 176 183
4 Saroja          62 F 24346 10 1 3 3 RE 336 234 6/36 6/12 14 12 3 3 RE 18.7 7.8 153 3 2 BE PRP RE GRID 29.18 7.3 6/24 6/12 3 3 NIL 6/24 6/12 3 3 NIL 176 172 6/24 6/12 3 4 LE 182 239
5 Kasthuri        56 F 35667 20 1 4 4 BE 341 329 6/60 3/60 12 14 4 4 BE 10.7 8.3 171 1 2 BE GRID PRP 26.05 7.9 6/60 3/60 4 4 BE 6/60 3/60 4 4 BE 323 301 3/60 3/60 5 5 BE 334 278
6 Jayalaskshmi    52 F 50179 10 1 4 3 BE 336 317 3/60 6/60 14 14 4 3 BE 17.7 8.2 165 1 2 BE GRID PRP 28.9 7.7 3/60 6/60 4 3 BE 3/60 6/60 4 3 RE 345 178 6/12 3/60 4 4 LE 179 299
7 Maheshwari      54 F 51739 20 1 4 4 BE 264 232 6/24 6/12 14 14 4 4 BE 12.7 8.4 175 1 1 BE GRID PRP 38.19 7.8 6/18 6/12 4 4 BE 6/18 6/12 4 4 RE 256 187 6/18 6/9 4 4 RE 242 176
8 Raju            62 M 52633 5 1 2 2 BE 245 243 6/18 6/18 14 14 2 2 BE 21.8 7.6 147 1 1 BE GRID PRP 46.12 7 6/12 6/18 2 2 LE 6/12 6/12 2 2 NIL 167 175 6/12 6/12 2 2 NIL 181 176
9 Gunasekaran     59 M 36639 15 1 1 1 RE 254 175 6/18 6/6 12 12 1 1 RE 28.2 7.4 141 2 2 RE GRID 56.19 6.7 6/18 6/6 1 1 RE 6/18 6/9 1 1 BE 243 231 6/18 6/9 1 1 LE 179 240
10 Albert          45 M 41340 8 1 2 2 RE 235 181 6/12 6/9 12 12 2 2 RE 21.2 7.5 143 2 2 BE PRP RE GRID 32.13 7.2 6/9 6/9 2 2 NIL 6/9 6/9 2 2 NIL 175 181 6/9 6/9 2 3 NIL 176 182
11 Selvaraj        49 M 46895 10 1 2 2 RE 248 179 6/18 6/9 14 12 2 2 RE 22.3 7.6 149 2 1 BE PRP RE GRID 48.6 7 6/12 6/9 2 2 NIL 6/12 6/9 2 2 NIL 178 186 6/12 6/9 2 2 NIL 184 176
12 Loganathan      53 M 56545 15 1 4 4 BE 276 254 6/24 6/12 18 18 4 4 BE 12.8 8.2 164 1 2 BE GRID PRP 37.9 7.7 6/18 6/12 4 4 BE 6/18 6/12 4 4 LE 179 278 6/18 6/12 4 4 LE 182 243
13 Jyotindra Gandhi 72 M 54549 7 1 2 2 BE 334 324 6/60 6/60 12 14 2 2 BE 22 7.5 139 2 2 BE GRID PRP 48.33 7.1 6/36 6/60 2 2 LE 6/12 6/12 2 2 NIL 184 176 6/12 6/12 2 2 NIL 179 184
14 Munniyammal     55 F 36556 5 1 1 1 RE 327 173 6/36 6/9 14 16 1 1 RE 26.3 6.8 121 2 2 RE GRID 53.21 6.8 6/18 6/12 1 1 NIL 6/18 6/9 1 1 NIL 189 174 6/18 6/9 1 1 NIL 175 182
15 Seetha          65 F 34788 3 1 1 1 NIL 177 181 6/12 6/6 12 14 1 1 NIL 26.6 7.3 134 2 2 NIL 54.33 6.7 6/12 6/6 1 1 NIL 6/12 6/6 1 1 NIL 185 179 6/12 6/6 1 1 NIL 182 175
16 Savitha         66 F 51676 2 1 1 1 NIL 183 176 6/6 6/12 16 14 1 1 NIL 27.5 6.9 123 2 2 NIL 54.21 6.6 6/6 6/12 1 1 NIL 6/6 6/12 1 1 NIL 178 183 6/6 6/12 1 1 NIL 187 179
17 Chandrasekar    70 M 24356 10 1 3 3 BE 236 245 6/12 6/18 14 12 3 3 BE 15.8 7.9 155 1 1 BE GRID PRP 40.92 7.4 6/18 6/18 3 3 RE 6/18 6/18 3 3 RE 245 177 6/18 6/18 3 3 NIL 178 185
18 Kumudha         56 F 54559 15 1 3 3 BE 314 298 6/36 6/12 18 18 3 3 BE 16.2 8 160 1 1 BE GRID PRP 39.54 7.4 6/24 6/12 3 3 NIL 6/24 6/12 3 3 NIL 186 175 6/24 6/12 3 3 NIL 174 182
19 Kalai selvi     67 F 45230 12 1 3 3 RE 247 176 6/18 6/9 14 14 3 3 RE 17.7 7.9 156 1 2 BE GRID PRP 42.14 7.4 6/18 6/12 3 3 LE 6/18 6/12 3 3 NIL 179 183 6/18 6/12 3 3 NIL 185 176
20 Krishnammal     55 F 32667 15 1 3 3 NIL 168 174 6/12 6/18 16 14 3 3 NIL 18.7 7.8 149 1 2 BE PRP 44.34 7.2 6/12 6/18 3 3 NIL 6/12 6/18 3 3 NIL 182 177 6/12 6/24 3 3 LE 179 245
21 Sanaullah       56 M 16170 13 2 4 4 BE 332 326 6/36 6/60 12 12 4 4 BE 9.1 8.4 180 3 1 BE GRID PRP 8.9 8.2 6/36 6/60 4 4 BE 6/36 0.78 5 5 RE 324 182 0.78 6/36 5 5 RE 304 175
22 Muthu           65 M 50274 18 2 4 4 BE 302 327 6/60 6/36 18 20 4 4 BE 10.5 8.4 175 1 2 BE GRID PRP 10.8 8.1 6/60 6/36 4 4 BE 6/60 6/60 5 5 BE 331 314 6/60 6/60 5 5 LE 183 277
23 Sundaram        65 M 49725 22 2 4 4 BE 238 278 6/18 6/24 14 14 4 4 BE 11.1 8.2 161 1 2 BE GRID PRP 11.08 8.2 6/18 6/24 4 4 BE 6/18 6/24 5 5 BE 254 256 6/18 6/18 5 5 BE 243 238
24 Anandhan        48 M 5048 20 2 4 4 BE 341 246 3/60 6/18 18 16 4 4 BE 11.5 8.2 163 1 2 BE GRID PRP 12.81 8.1 3/60 6/18 4 4 BE 6/60 6/18 5 4 NIL 184 174 6/60 6/18 5 4 NIL 179 185
25 Kasinathan      55 M 66304 10 2 2 2 BE 273 268 6/24 6/24 14 14 2 2 BE 18.3 7.5 143 1 1 BE GRID PRP 17.21 7.5 6/12 6/24 2 2 LE 6/12 6/18 2 2 NIL 175 182 6/12 6/18 4 3 RE 246 175
26 Shekar          43 M 64012 7 2 1 1 BE 256 242 6/18 6/12 14 14 1 1 BE 18.8 6.9 123 2 2 BE GRID 17.71 6.7 6/18 6/12 1 1 LE 6/12 6/9 1 1 NIL 173 179 6/12 6/9 1 1 NIL 171 185
27 Ravichandran    48 M 52584 14 2 1 1 BE 328 319 6/36 6/36 18 16 1 1 BE 23.5 6.8 120 2 2 BE GRID 21.42 6.8 6/36 6/36 1 1 BE 6/36 6/36 1 1 BE 278 256 6/24 6/24 1 1 NIL 186 173
28 Kumaran         54 M 49548 15 2 2 2 BE 231 334 6/12 3/60 14 14 2 2 BE 20.5 7.6 162 2 2 BE GRID PRP 22.35 7.4 6/9 6/36 2 2 NIL 6/9 6/12 2 2 NIL 186 176 6/9 6/12 2 5 NIL 174 186
29 Rachel          69 F 15431 12 2 2 2 NIL 187 179 6/18 6/12 18 18 2 2 NIL 22.4 7.5 154 2 1 BE PRP 21.09 7.5 6/18 6/12 2 2 NIL 6/18 6/12 2 2 NIL 189 173 6/18 6/12 2 5 NIL 187 176
30 Mahesh          55 M 60690 5 2 1 1 RE 243 172 6/18 6/6 14 14 1 1 RE 26.5 7.4 143 2 2 RE GRID 24.81 7.2 6/18 6/6 1 1 RE 6/9 6/6 1 1 NIL 176 185 6/9 6/6 1 1 NIL 172 183
31 Kadhiresan      43 M 62087 8 2 1 1 BE 328 316 3/60 6/60 12 12 1 1 BE 29.9 7.3 139 2 2 BE GRID PRP 30.22 7.3 6/24 6/24 1 1 NIL 6/24 6/24 1 1 NIL 178 171 6/12 6/12 1 1 NIL 209 175
32 Rajendran       50 M 60549 10 2 1 1 NIL 174 183 6/6 6/9 14 14 1 1 NIL 42.5 7.4 135 2 2 NIL 41.9 7 6/6 6/9 1 1 NIL 6/6 6/9 1 1 NIL 179 185 6/12 6/9 1 1 RE 245 178
33 Pappathi        55 F 60783 17 2 4 4 BE 236 244 6/12 6/18 14 12 4 4 BE 15.6 8.3 173 1 1 BE GRID PRP 15.31 8.1 6/12 6/18 4 4 BE 6/12 6/12 5 4 NIL 183 179 6/12 6/12 4 4 LE 179 237
34 Jyothi          65 F 61154 5 2 2 2 BE 239 279 6/12 6/24 14 14 2 2 BE 21.3 7.6 139 2 2 BE GRID PRP 23.45 7.5 6/9 6/24 2 2 LE 6/9 6/18 2 2 NIL 185 177 6/9 6/18 2 2 NIL 176 186
35 Devaki          67 F 63445 10 2 3 3 BE 246 256 6/18 6/18 14 16 3 3 BE 15.8 8 153 3 2 BE GRID PRP 16.81 7.8 6/12 6/12 3 3 NIL 6/12 6/12 3 3 NIL 187 175 6/12 6/12 4 4 NIL 175 183
36 Arumugam        54 M 61224 5 2 2 1 NIL 178 183 6/9 6/6 12 12 2 1 NIL 32.3 7.4 138 2 2 RE PRP 30.32 7.4 6/9 6/6 2 1 NIL 6/9 6/6 2 1 NIL 184 173 6/12 6/6 2 1 RE 236 176
37 Nithya          60 F 54089 10 2 3 3 NIL 179 176 6/12 6/9 12 14 3 3 NIL 21.1 7.8 155 1 1 BE PRP 22.31 7.7 6/12 6/9 3 3 NIL 6/12 6/9 3 3 NIL 174 184 6/12 6/9 4 5 NIL 185 179
38 Sakunthala      59 F 56678 7 2 3 3 LE 177 254 6/9 6/18 14 14 3 3 LE 18.4 7.9 149 1 2 BE PRP LE GRID 19.22 7.9 6/9 6/9 3 3 NIL 6/9 6/9 3 3 NIL 172 183 6/9 6/9 4 4 NIL 178 183
39 Shantha         55 F 62455 15 2 3 3 BE 237 242 6/12 6/9 12 12 3 3 BE 17.2 7.9 159 1 2 BE PRP BE GRID 19.19 7.7 6/12 6/9 3 3 BE 6/9 6/9 3 3 LE 182 231 6/9 6/9 4 5 LE 179 245
40 Rajeshwari      64 F 45667 10 2 3 3 BE 316 247 6/36 6/18 16 16 3 3 BE 16 7.8 152 1 2 BE GRID PRP 15.7 7.8 6/36 6/9 3 3 RE 6/18 6/9 3 3 NIL 184 179 6/18 6/9 4 4 NIL 184 172
MASTER CHART
